72 Pinchas Rosen Street
|
Tel-Aviv 69512, Israel
|
(Address of Principal Executive Offices)
|
10.1*
|
Amendment to Funding Agreement by and between Baize Investments (Israel) Ltd. and Compugen Ltd., dated April 21, 2013.
|
99.1
|
Unaudited interim consolidated financial statements as of and for the six months ended June 30, 2013.
|
99.2
|
Operating and Financial Review and Prospects as of and for the six months ended June 30, 2013 and June 30, 2012.
|
99.3
|
Notice and proxy statement relating to the special general meeting of shareholders of Compugen Ltd. to be held on September 10, 2013.
|
101@
|
The following financial information from Compugen Ltd.’s Report on Form 6-K, formatted in XBRL (eXtensible Business Reporting Language): (i) consolidated balance sheets at June 30, 2013 and December 31, 2012; (ii) Consolidated of Comprehensive Loss for the six months ended June 30, 2013 and 2012; (iii) consolidated statements of changes in shareholders’ equity for the six months ended June 30, 2013 and the year ended December 31, 2012; (iv) consolidated statements of cash flows for the six months ended June 30, 2013 and 2012; and (v) notes to the unaudited consolidated financial statements.
|
*
|
Confidential portions of this document have been filed separately with the SEC pursuant to a request for confidential treatment.
|
@
|
Users of this data are advised, in accordance with Rule 406T of Regulation S-T promulgated by the SEC, that this Interactive Data File is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.
|
COMPUGEN LTD.
|
|||
Date: August 2, 2013
|
By:
|
/s/
Dikla Czaczkes Axselbrad
|
|
Dikla Czaczkes Axselbrad
|
|||
Chief Financial Officer
|
1.
|
The Parties hereby agree to terminate in its entirety the 2011 Agreement.
|
2.
|
All defined terms used herein but not defined herein, shall have the respective meanings as set forth in the 2010 Agreement.
|
3.
|
The second WHEREAS clause in the 2010 Agreement will be replaced by the following:
|
4.
|
Section 1.1 of the 2010 Agreement, will be replaced by the following:
|
“1.1
.
|
“
Affiliate
” shall mean any company or other legal entity which, directly or indirectly, controls, or is controlled by, or is under common control with, Compugen; control means the ability to direct the operations of any company or other legal entity, including, without limitation, the holding of fifty (50%) or more of (i) the capital and/or (ii) the voting rights or general partnership interest and/or (iii) the right to elect or appoint directors, and/or (iv) the right to receive profits.”
|
5.
|
Section 1.1A will be added to the 2010 Agreement as follows:
|
“1.1A
|
“
Annual Report
” shall mean an annual report containing a summary report for each Designated Product Candidate and Target mAb (as such term is hereinafter defined), providing general information with respect to what research was conducted by Compugen since the prior Annual Report, and what is planned to be undertaken during the remainder of the current calendar year. The Annual Report shall also contain general information as to any commercialization efforts taken (and planned to be taken) and agreements reached (and planned to be reached) in respect of the Designated Product Candidates and Target mAbs during the period covered by such report. The Annual Report shall be duly signed by either the CEO, CFO or COO of Compugen and shall be subject to the confidentiality provisions hereof.”
|
6.
|
Section 1.3 of the 2010 Agreement, will be replaced by the following:
|
|
“1.3
|
“
Cash Consideration
” shall mean the amounts payable by Compugen to the Investor in respect of Gross Cash, which shall equal ten percent (10%) of Net Cash.”
|
7.
|
Section 1.4 of the 2010 Agreement, will be replaced by the following:
|
|
“1.4
|
“
Compugen
Warrant
”
shall mean a warrant setting forth the right of the Investor to purchase Ordinary Shares for an exercise price of seven U.S. dollars and fifty cents ($7.50) per Ordinary Share, to be exercised no later than June 30, 2015, in the form attached hereto as
Exhibit B
.”
|
8.
|
Sections 1.5 and 1.6 will be deleted from the 2010 Agreement.
|
9.
|
Section 1.7A will be added to the 2010 Agreement as follows:
|
“1.7A.
|
“
Gross Cash
” shall mean
all cash consideration received by Compugen or its Affiliates from third parties on the earlier of;
|
|
X.
|
any day (i) on or prior to June 30, 2015 with respect to any Designated Product Candidate and/or Target mAb; and (ii) on or after July 1, 2015 with respect to the Selected Products; or
|
|
Y.
|
if applicable, on or prior to the Exchange Notice Date (as such term is hereinafter defined).
”
|
10.
|
Section 1.7B will be added to the 2010 Agreement as follows:
|
“1.7B.
|
“Monoclonal Antibody
” or
“mAb
” shall mean an antibody produced by a single clone of cells or cell line.”
|
11.
|
Section 1.7C will be added to the 2010 Agreement as follows:
|
“1.7C
|
“
Net Cash
” shall mean Gross Cash minus Pass-Through Amounts.”
|
12.
|
Section 1.13 will be replaced by the following:
|
“1.13
|
“
Pass-Through Amounts
” shall mean: (i) out-of-pocket cash payments by Compugen or its Affiliates to subcontractors directly related to a Designated Product Candidate, or Target mAb provided that such cash payments become payable by Compugen
following
the closing of the third party agreement giving rise to the Gross Cash received by Compugen on which the related Cash Consideration is based; (ii) Third Party Royalties paid in connection with the Gross Cash received by Compugen on which the related Cash Consideration is based; (iii) the amount of any taxes withheld at source for which Compugen cannot receive a tax credit under then prevailing laws; (iv) any payments made at fair market value for equity investments in Compugen as part of a transaction in connection with the Gross Cash received by Compugen on which the related Cash Consideration is based; (v) research funding paid to Compugen under a written agreement with a research project and a budget intended to further research and development with respect to such Designated Candidates and Target mAbs; and (vi) arm's length loans provided to Compugen under the third party agreement giving rise to the Gross Cash received by Compugen on which the related Cash Consideration is based. For the avoidance of doubt, (i) each such Pass-Through Amount shall be subject to only one recovery by Compugen and (ii) reimbursement of out-of-pocket cash payments by Compugen to subcontractors incurred by Compugen
prior to
the closing of the third party agreement giving rise to the Gross Cash on which the related Cash Consideration is based, shall
not
be considered as Pass-Through Amounts for the purposes of this Agreement.
|
13.
|
Section 1.15 will be deleted from the 2010 Agreement.
|
14.
|
Section 1.16 will be added to the 2010 Agreement as follows:
|
“
1.16
|
“Selected Products”
shall mean a total of five (5) Designated Product Candidates and Target mAbs as selected by Investor on or prior to the later of (i) June 30, 2015, or (ii) thirty (30) days following receipt by Investor of the Annual Report for calendar year 2014, pursuant to Section 3A hereunder.”
|
15.
|
Section 1.17 will be added to the 2010 Agreement as follows:
|
|
“1.17
|
“
Target
”
shall mean each of the eight (8) drug targets identified by Compugen and listed in
Appendix A
2 to this Agreement.”
|
16.
|
Section 1.18 will be added to the 2010 Agreement as follows:
|
|
“1.18
|
“
Target mAb
” shall mean any mAb developed for the treatment of disease or other conditions in humans or animals by or on behalf of Compugen or any Affiliate of Compugen against a Target.”
|
17.
|
Section 1.19 will be added to the 2010 Agreement as follows:
|
|
“1.19
|
“
Third Party Royalties
” shall mean any royalties or percentage payments to be paid by Compugen or an Affiliate of Compugen to any third party in connection with, or in consideration for, a license granted by such third party to technology and/or intellectual property rights needed for the making, using, marketing or selling of a Designated Product Candidate and/or Target mAb.
|
18.
|
Section 3.1.2 of the 2010 Agreement will be replaced by the following:
|
“3.1.2
|
An entitlement to receive the Cash Consideration.”
|
19.
|
Section 3.1.3 will be deleted from the 2010 Agreement.
|
20.
|
Section 3.1.4 of the 2010 Agreement will be replaced by the following:
|
“3.1.4
|
An entitlement to receive the Annual Reports and the Cash Consideration Quarterly Reports mentioned in Section 3.3 below.”
|
21.
|
Section 3.2 of the 2010 Agreement will be replaced by the following:
|
|
“3.2
|
Compugen shall issue to Investor the Annual Reports not later than 60 days following Company’s filing of its Form 20-F Annual Report with the SEC for calendar years 2012, 2013 and 2014.”
|
22.
|
Section 3.3 of the 2010 Agreement will be replaced by the following:
|
|
“3.3
|
Payments of Cash Consideration pursuant to 3.1.2 above shall be made quarterly within 120 days following the end of each calendar quarter, during which any Gross Cash was received. Such payments shall be in total only and shall be paid together with a validity report signed by the CFO of the Company (the “Cash Consideration Quarterly Report”). At Investor's request no later than two years following each such payment, Investor will have an audit right at Compugen’s premises, to be performed by a recognized accounting firm (chosen by Investor) during normal business hours and subject to the signature of a customary confidentiality undertaking. The cost of such auditing shall be borne by Investor, unless a deficiency of more than 2% is found, in which event Compugen shall bear all reasonable auditing costs. Within thirty (30) days of such auditing, the Party which either received an excessive amount, or paid an amount lower than required, according to the auditing, shall pay the appropriate amount, provided that if such payment is made by Compugen it shall be paid together with interest at an annual rate of five percent (5%) from the due date and until actual payment hereunder.
|
23.
|
Section 3.8 of the 2010 Agreement will be replaced by the following:
|
|
“3.8
|
Notwithstanding the above, Investor may, at any time on or prior to June 30, 2015 provide a written notice (the “
Exchange Option Notice
”) of its election to exchange, as of the Actual Exchange Date (as such term is hereinafter defined), all of its rights to receive the full Cash Consideration for the Exchange Shares (as such term is hereinafter defined) without any further consideration required to be paid by the Investor to Compugen in connection therewith (the right to provide the Exchange Option Notice and instead receive the Exchange Shares, the “
Exchange Option
”). The “
Actual Exchange Date
” shall be a date selected by the Investor and set forth in the Exchange Option Notice, provided that such date shall not be earlier than 61 trading days following the date of delivery of such Exchange Option Notice to Compugen (the “
Exchange Notice Date
”), nor later than the 62
nd
trading day following June 30, 2015.
|
24.
|
Section 3.10 of the 2010 Agreement will be replaced by the following:
|
|
“3.10
|
For the avoidance of doubt, in the event of the Investor providing Compugen with an Exchange Notice, the Investor shall not be entitled to receive any further Cash Consideration or Cash Consideration Reports with respect to Net Cash received by Compugen following the Exchange Notice Date, and
|
|
3.10.1
|
All Compugen Warrants issued to Investor shall remain outstanding in full with no change to their terms or conditions.
|
|
3.10.2
|
Other than with respect to (i) the issuance of the Exchange Shares, (ii) the Compugen Warrants and (iii) any Compugen obligations related to the period on or prior to the Exchange Notice Date, Compugen shall have no further financial or other obligations of any kind to Investor.
|
25.
|
Section 3.11 will be deleted
|
26.
|
Section 3A will be added to the 2010 Agreement as follows:
|
|
3A.1
|
At any time, or from time to time, but in any event prior to the later of (i) June 30, 2015, or (ii) the date that is thirty (30) days following receipt by Investor of the Annual Report for calendar year 2014, (in either case, the “
Final Date
”) Investor shall notify Company in writing of its selection of a total of not more than five (5) Designated Product Candidates and Target mAbs to be Selected Products under this Agreement.
|
|
3A.2
|
Once a Designated Product Candidate or Target mAb, is selected by the Investor, it shall remain a Selected Product for the entire term of the Agreement.
|
|
3A.3
|
If no Selected Product has been selected by Investor 30 days prior to the Final Date, Compugen shall, within the following five business days, notify Investor in writing that this is the case. If no Selected Product has been selected by Investor 15 days prior to the Final Date, Compugen shall again, within the following five business days, notify Investor in writing that this is the case.
|
|
3A.4
|
For the avoidance of doubt, if no Selected Product has been selected by Investor prior to the Final Date, it shall be deemed that as of the Final Date, Investor has elected to exercise the Exchange Option pursuant to Section 3.8 above and therefore the Exchange Notice Date shall be the Final Date.
|
27.
|
Section 6 of the 2010 Agreement will be replaced by the following:
|
1.
|
“6.
|
INVENTIONS
|
|
Investor agrees that all information, improvements, inventions, formulae, processes, techniques, know-how and data, and all related intellectual property, whether or not patentable or registerable under copyright or any similar laws, made or conceived or reduced to practice or learned in connection with any of the Designated Product Candidates, Targets and/or Target mAbs (all such information, improvements, inventions, formulae, processes, techniques, know-how, and data, and all related intellectual property, are hereinafter referred to as the “
Invention(s)
”) immediately upon discovery, receipt, creation or invention as applicable, shall be considered Inventions of the Company, shall be the sole property of the Company and its assignees, and the Company and its assignees shall be the sole owner of all patents, copyrights, trade secret and all other rights of any kind or nature, including moral rights, in connection with such Inventions.”
|
28.
|
Section 7.1 of the 2010 Agreement will be replaced by the following:
|
|
7.1.1
|
Receipt by Investor of the Exchange Shares pursuant to Section 3.8 above; or
|
|
7.1.2
|
December 31, 2030,
|
29.
|
Section 7.2.2 of the 2010 Agreement will be replaced by the following:
|
30.
|
Section 7.3 of the 2010 Agreement will be replaced by the following:
|
31.
|
Section 7.4 of the 2010 Agreement will be replaced by the following:
|
32.
|
Exhibit A of the 2010 Agreement will be replaced by Exhibits A1 and A2 attached to this Amendment.
|
33.
|
Exhibit B of the 2010 Agreement will be replaced by Exhibit B1 attached to this Amendment.
|
34.
|
In the event of any conflict between the provisions of the 2010 Agreement as amended by this Amendment, the provisions of this Amendment shall prevail. For avoidance of doubt a copy of the 2010 Agreement as amended by this Amendment is attached.
|
35.
|
Except as amended herein, all other terms and conditions of the 2010 Agreement shall remain in full force and effect.
|
36.
|
This Amendment may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Any signature page delivered by facsimile or electronic image transmission shall be binding to the same extent as an original signature page.
|
37.
|
IN WITNESS WHEREOF, the parties have executed this Amendment as of the date hereof.
|
BAIZE INVESTMENTS (ISRAEL) LTD |
COMPUGEN LTD.
|
|||
By:
|
/s/ Murray Goldman |
By:
|
/s/ Anat Cohen-Dayag
|
|
Name:
|
Murray Goldman |
|
Name:
|
Anat Cohen-Dayag
|
|
||||
Title:
|
President |
|
Title:
|
President & CEO
|
Date:
|
April 19, 2013 |
Date:
|
April 21, 2013
|
|
|
Designated Product Candidates
|
Status |
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
Targets
|
Status
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
Page
|
|
2 - 3
|
|
4
|
|
5
|
|
6 - 7
|
|
8 - 15
|
Six months ended
June 30,
|
||||||||
2013
|
2012
|
|||||||
Unaudited
|
||||||||
Revenues
|
$ | 184 | - | |||||
Cost of revenues
|
234 | - | ||||||
Gross loss
|
(50 | ) | - | |||||
Operating expenses:
|
||||||||
Research and development expenses, net
|
6,176 | 4,047 | ||||||
Marketing and business development expenses
|
352 | 351 | ||||||
General and administrative expenses
|
2,105 | 1,679 | ||||||
Total
operating expenses
|
8,633 | 6,077 | ||||||
Operating loss
|
(8,683 | ) | (6,077 | ) | ||||
Financial income, net
|
2,270 | 1,332 | ||||||
Net loss
|
$ | (6,413 | ) | $ | (4,745 | ) | ||
Unrealized gain arising during the period on Investment in Evogene
|
$ | 924 | $ | 569 | ||||
Realized gain (loss) arising during the period on Investment in
Evogene
|
$ | (1,453 | ) | $ | - | |||
Total comprehensive loss
|
$ | (6,942 | ) | $ | (4,176 | ) | ||
Basic net loss per share
|
$ | (0.17 | ) | $ | (0.13 | ) | ||
Weighted average number of Ordinary shares used in computing basic
net loss per share
|
37,746,520 | 35,628,390 | ||||||
Diluted net loss per share
|
$ | (0.18 | ) | $ | (0.13 | ) | ||
Weighted average number of Ordinary shares used in computing diluted
net loss per share
|
39,140,651 | 35,628,390 |
Ordinary
shares
|
Additional paid-in
|
Accumulated other comprehensive
|
Accumulated
|
Total shareholders'
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
income
|
deficit
|
equity
|
|||||||||||||||||||
Balance as of January 1, 2012
|
34,707,622 | $ | 94 | $ | 195,714 | $ | 4,264 | $ | (180,491 | ) | $ | 19,581 | ||||||||||||
Employee options exercised
|
696,988 | 2 | 1,878 | - | - | 1,880 | ||||||||||||||||||
Issuance of shares
|
1,185,868 | 3 | 6,264 | - | - | 6,267 | ||||||||||||||||||
Stock-based compensation relating to options and warrants issued to consultants , employees
and directors
|
- | - | 2,469 | - | - | 2,469 | ||||||||||||||||||
Other comprehensive income
|
- | - | - | 1,103 | - | 1,103 | ||||||||||||||||||
Net loss
|
- | - | - | - | (13,628 | ) | (13,628 | ) | ||||||||||||||||
Balance as of December 31, 2012
|
36,590,478 | 99 | 206,325 | 5,367 | (194,119 | ) | 17,672 | |||||||||||||||||
Employee options exercised
|
432,687 | 1 | 1,167 | - | - | 1,168 | ||||||||||||||||||
Issuance of shares
|
1,338,285 | 4 | 7,264 | - | - | 7,268 | ||||||||||||||||||
Stock-based compensation relating to options issued to consultants, employees and directors
|
- | - | 1,388 | - | - | 1,388 | ||||||||||||||||||
Classification of liability with respect to outstanding options to non-employee to equity
|
- | - | 160 | - | - | 160 | ||||||||||||||||||
Other comprehensive loss
|
- | - | - | (529 | ) | - | (529 | ) | ||||||||||||||||
Net loss
|
- | - | - | - | (6,413 | ) | (6,413 | ) | ||||||||||||||||
Balance as of June 30, 2013 (unaudited)
|
38,361,450 | $ | 104 | $ | 216,304 | $ | 4,838 | $ | (200,532 | ) | $ | 20,714 |
Six months ended
June 30,
|
||||||||
2013
|
2012
|
|||||||
Unaudited
|
||||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$ | (6,413 | ) | $ | (4,745 | ) | ||
Adjustments required to reconcile net loss to net cash used in operating activities:
|
||||||||
Non-cash stock-based compensation
|
1,388 | 1,070 | ||||||
Depreciation
|
237 | 116 | ||||||
Severance pay, net
|
26 | 61 | ||||||
Gain from the sale of Evogene shares
|
(1,453 | ) | - | |||||
Change in fair value of exchange option and embedded derivatives within research and development funding arrangements
|
(467 | ) | (1,313 | ) | ||||
Amortization of the cash consideration of the second research and development funding arrangement
|
(104 | ) | (44 | ) | ||||
Change in the fair value of liability with respect to outstanding options to non-employee
|
(104 | ) | - | |||||
Increase in other accounts receivable and prepaid expenses
|
(105 | ) | (123 | ) | ||||
Decrease (increase) in long-term prepaid expenses
|
100 | (400 | ) | |||||
Increase (decrease) in trade payables and other accounts payable and accrued expenses
|
581 | (165 | ) | |||||
Net cash used in operating activities
|
(6,314 | ) | (5,543 | ) | ||||
Cash flows from investing activities:
|
||||||||
Proceeds from maturity of short-term bank deposits
|
3,215 | 16,525 | ||||||
Investment in short-term bank deposits
|
(15,015 | ) | (13,107 | ) | ||||
Decrease (increase) in long-term lease deposits
|
37 | (51 | ) | |||||
Purchase of property and equipment
|
(102 | ) | (315 | ) | ||||
Proceeds from sale of investment in Evogene
|
1,407 | - | ||||||
Net cash provided by (used in) investing activities
|
(10,458 | ) | 3,052 | |||||
Cash flows from financing activities:
|
||||||||
Proceeds from issuance of ordinary shares, net
|
7,324 | 3,663 | ||||||
Proceeds from research and development funding arrangement
|
5,000 | - | ||||||
Proceeds from exercise of options
|
1,168 | 1,769 | ||||||
Net cash provided by financing activities
|
13,492 | 5,432 | ||||||
Increase (decrease) in cash and cash equivalents
|
(3,280 | ) | 2,941 | |||||
Cash and cash equivalents at the beginning of the period
|
16,374 | 5,846 | ||||||
Cash and cash equivalents at the end of the period
|
$ | 13,094 | $ | 8,787 |
Six months ended
June 30,
|
||||||||
2013
|
2012
|
|||||||
Unaudited
|
||||||||
Supplemental disclosure of non-cash investing and financing activities:
|
||||||||
Purchase of property and equipment
|
$ | 111 | $ | - |
|
a.
|
Compugen Ltd. (the "Company") and its subsidiary is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. Unlike traditional high throughput trial and error experimental-based drug candidate discovery, the Company's discovery efforts are based on systematic and continuously improving in silico (by computer) product candidate prediction and selection followed by experimental validation, with selected product candidates being advanced in our Pipeline Program to the pre-IND stage. The Company's in silico predictive models utilize a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities. The Company's business model primarily involves collaborations covering the further development and commercialization of in house-discovered product candidates and various forms of research and discovery agreements, in both cases providing us with potential milestone payments and royalties on product sales or other forms of revenue sharing.
The Company's headquarters are located in Israel, with research and development facilities in Israel and California through its wholly-owned U.S. subsidiary, Compugen USA, Inc. ("Compugen Inc.")
|
|
b.
|
Investment in Evogene:
The Company accounts for its investment in Evogene Ltd.(“Evogene”) in accordance with ASC 320, "Investments - Debt and Equity Securities".
Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date.
The Company classifies its investment in Evogene as available-for-sale securities. Available-for-sale securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in "accumulated other comprehensive income (loss)" in shareholders' equity and statement of comprehensive income. Realized gains and losses are included in other income and are derived using the specific identification method for determining the cost of securities. As of June 30, 2013, the Company holds 787,585 of Evogene Ordinary shares representing 2.09% of Evogene outstanding Ordinary shares.
|
|
c.
|
On April 19, 2013, the Company received from the research and development funding arrangements investor the remaining funding amount of $5,000 under the second funding arrangement (the “mAb Funding Arangement”). For further information about the funding arrangements, refer to Note 8 to the Company’s consolidated financial statements contained in the Company’s Annual Report on Form 20-F for the year ended December 31, 2012.
According to the funding arrangements prior the April 2013 the investor was entitled to receive a portion of future income received by the Company related to commercialization and post-marketing fees for certain designated product candidates ("Participation Rights"). In addition, the investor had the right, to waive its Participation Rights in exchange for the Company's Ordinary Shares (the "Exchange Option").
In connection with final $5,000 investment under the mAb Funding Arrangement, the Company entered into the Amendment to Funding Arrangements (the “2013 Amendment”), pursuant to which the following terms would apply to all investments under the funding arrangement and its amendments:
|
|
1.
|
The mAb Funding Arrangement was terminated.
|
|
2.
|
Until June 30, 2015, the investor has the right to receive 10% of the cash consideration received by the Company or its affiliates from third parties, less certain pass-through amounts, with respect to certain designated product candidates (the “Amended Participation Rights”).
|
|
3.
|
The Exchange Option term has been extended to June 30, 2015 and the exchange shares amount will be determined based on total aggregated funding amount of $ 13,000 in connection to the research and development funding agreements, less 50% of any Amended Participation Rights paid to investor by Compugen, divided by the average closing price of the Company's Ordinary shares during twenty (20) trading days prior the actual exchange date provided however that the exchange price shall not be lower than $3.00 per share, and shall not exceed $12.00 per share.
|
|
4.
|
The warrants granted to the investor under previous funding arrangements to purchase up to 500,000 of the Company’s ordinary shares under the first research and development funding arrangement has been replaced with a new warrant to purchase up to 500,000 of the Company’s ordinary shares, exercisable at $ 7.50 per share through June 30, 2015.
|
|
d.
|
Following a shelf registration filed in January 2011, the Company signed in August 2011 an agreement with a broker, to issue and sell Ordinary shares under an At-the-Market offering ("ATM") program with gross proceeds of up to $ 40,000. During the six months period ended June 30, 2013 the Company had raised approximately $ 7,268, net of issuance expenses, under this program from the issuance of 1,338,285 of its Ordinary shares.
|
|
a.
|
The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013.
|
|
b.
|
Under ASU 2013-02, "Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income", the Company is required to provide information about the amounts re-classified out of Accumulated Other Comprehensive Income ("AOCI") by component. In addition, the Company is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts.
|
|
The Company adopted the provision of ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820") on January 1, 2008. ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.
ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. ASC 820 establishes three levels of inputs that may be used to measure fair value:
|
Level 1 -
|
quoted prices in active markets for identical assets or liabilities;
|
|
Level 2 -
|
inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
|
|
Level 3 -
|
unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
Fair value
of embedded derivatives
|
||||
Balance at January 1, 2012
|
$ | 5,707 | ||
Fair value of Exchange Option within the 2012 proceeds under the
second research and development arrangement
|
569 | |||
Change in fair value of Exchange Option and embedded
derivatives within research and development arrangements
|
588 | |||
Balance at December 31, 2012 *)
|
6,864 | |||
Fair value of Exchange Option within the 2013 proceeds under the
second research and development arrangement
|
4,756 | |||
Change in fair value of Exchange Option and embedded
derivatives within research and development arrangements
|
(467 | ) | ||
Balance at June 30, 2013 (unaudited) *)
|
$ | 11,153 |
|
*)
|
The amount on the balance sheets of the research and development funding arrangements and others includes also a mAb Participation Interest in the amount of $ 884 and $ 744 as of June 30, 2013 and December 31, 2012, respectively, and fair value of liability with respect to outstanding options to a non-employee in the amount of $0 and $ 264 as of June 30, 2013 and December 31, 2012, respectively.
|
|
a.
|
The Company provided bank guarantees in the amount of $ 99 and check deposit in the amount of $ 40 in favor of its offices' lessor in Israel and California, U.S, respectively.
|
b.
|
Commitments in favor of the Government of Israel and other grants:
|
|
1.
|
As of June 30, 2013, the Company's aggregate contingent obligations for payments to the Office of the Chief Scientist, ("OCS"), based on OCS participation in certain potential future receipts or revenue accruals, net of interest, royalties paid or accrued, totaled approximately $ 8,762.
|
|
2.
|
Under the OCS royalty-bearing programs, the Company is not obligated to repay any amounts received from the OCS if it does not generate any income from the results of the OCS funded research programs. If any such research programs are successful and income is generated, the Company is committed to pay royalties at a rate of 3% to 5% of the Company's revenues arising from such research program, up to a maximum of 100% of the amount received for such program from the OCS, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR).
|
|
For the six-months ended June 30, 2013, the Company has an aggregate of paid and accrued royalties to the OCS recorded in the consolidated statement of comprehensive loss in the amount of $ 6.
|
|
3.
|
As of June 30, 2013 under the 2013 Amendment the investor is entitled to receive Amended Participation Rights. As of December 31, 2012 under the research and development funding arrangement and the mAb Funding Arrangement the investor was entitled to receive Participation Rights and mAb Participation Interest, respectively. As of June 30, 2013 and December 31, 2012 the Company did not incur any obligation under these arrangements.
|
|
4.
|
On June 25, 2012 the Company and its U.S subsidiary added to its mAb enabling technology base by entering into an Antibodies Discovery Collaboration Agreement (the "Agreement") with a U.S. antibody technology company ("mAb Technology Company"), providing an established source for fully human mAbs. The Agreement includes time based research and commercial licenses to use specific mAb Technology Company proprietary collections of polynucleotides encoding antibodies, and their associated biological materials, together with the systems and/or licensed know how and/or to practice patent rights to identify, isolate, and modify discovery Fabs (the "Technology"), and to develop and exploit discovery products. According to the Agreement (i) the Company paid $ 600 in consideration for a three-year access right to the Technology, of which $ 400 was recorded as long-term prepaid expenses and will be charged to the statement of comprehensive loss over three years and (ii) $ 150 in consideration for the associated biological materials, which was recorded as other accounts receivables and prepaid expenses and will be charged to the statement of comprehensive loss in accordance with actual use of materials during each measured period and
(iii) in the event any Compugen mAb programs utilize the Technology, the Company would pay additional fees upon the occurrence of certain development and commercialization milestone up to a maximum cumulative total of $ 3,250 for each antibody drug product that achieved all such milestone events. In addition, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as "Contingent Fees"). As of June 30, 2013 and December 31, 2012 the Company did not incur any obligation for such Contingent Fees.
|
|
In December 2012, the Company replenished the associated biological materials to support the research and development activities performed under the Agreement in the amount of $ 100 which was recorded as other accounts receivables and prepaid expenses.
During the period from June 25, 2012 to December 31, 2012 and the six-month period ended June 30, 2013, the Company charged expenses to the statement of comprehensive loss in the amount of $ 109 and $ 158, respectively, related to the Agreement.
|
|
During the six-month period ended June 30, 2013, the Company's Board of Directors granted options to purchase a total of 217,500 Ordinary shares of the Company. 102,500 and 115,000 options were granted to employees and non-employees, respectively. The exercise prices for such options are from $ 4.92 to $ 5.50 per share, with vesting to occur in up to 4 years.
The following table presents the weighted-average assumptions used to estimate the fair values of the options granted in the periods presented:
|
Six months ended
June 30,
|
||||||
2013
|
2012
|
|||||
Volatility
|
58%-83% | 73%-88% | ||||
Risk-free interest rate
|
0.54%-1.59% | 0.56%-2.00% | ||||
Dividend yield
|
0% | 0% | ||||
Expected life (years) *)
|
4.0 – 6.0 | 3.8-4.7 |
|
*)
|
Excluding options that were granted to a consultant in connection with the mAb Funding Arrangement.
|
|
Weighted average fair value of options granted during the six-month periods ended June 30, 2013 and 2012 are $ 2.96 and $ 3.70, respectively.
As of June 30, 2013, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $ 4,309, which is expected to be recognized over a weighted average period of approximately 2.12 years.
|
Six months ended
June 30,
|
||||||||
2013
|
2012
|
|||||||
Interest income
|
$ | 82 | $ | 190 | ||||
Change in fair value of Exchange Option and embedded derivatives
and outstanding options to non-employee within research and
development funding arrangements
|
571 | 1,313 | ||||||
Financial income from selling of Evogene shares
|
1,453 | - | ||||||
Exchange rate differences and others
|
164 | (171 | ) | |||||
Financial income, net
|
$ | 2,270 | $ | 1,332 |
|
The Company provides research and development services to one of its affiliates Neviah Genomics in consideration for pre-scheduled determined fees. During the six-month periods ended June 30, 2013 and June 30, 2012, the Company recognized $ 184 and $ 0 in revenues, respectively, from such agreement.
|
|
On July 15, 2013, the Company's Board of directors approved a grant to employees and non-employees of options to purchase a total of 1,018,900 and 10,000 ordinary shares, respectively, at an exercise price of $ 5.445 per share.
1,008,900 out of the total options to purchase ordinary shares granted to employees shall vest over a period of twelve months commencing January 1, 2016.
10,000 out of the total options to purchase ordinary shares granted to employees shall vest over a period of four years commencing on the above date.
|
|
10,000 options to purchase ordinary shares granted to non- employees shall vest over a period of twelve months commencing on the above date.
180,000 options out of the total options to purchase ordinary shares granted to employees are pending shareholders’ approval.
|
1.
|
To approve and adopt new Articles of Association of the Company;
|
2.
|
To approve a compensation policy with respect to the terms of office and employment of the Company’s “office holders” (as such term is defined in the Israeli Companies Law, 5759-1999, as amended);
|
3.
|
To ratify and approve: (1) the remuneration to be provided to the non-management directors of the Company; and (2) director and officer liability insurance coverage, the exemption and indemnification of the directors and chief executive officer of the Company and the provision of letters of indemnification and exemption to them;
|
4.
|
To approve the grant of options to purchase 60,000 ordinary shares NIS 0.01 nominal (par) value each, to the chairman of the board of directors of the Company and the grant of options to purchase 120,000 ordinary shares NIS 0.01 nominal (par) value each, to the chief executive officer of the Company; and
|
5.
|
To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
By Order of the Board of Directors,
/S/ Mr. Martin S. Gerstel
Martin S. Gerstel, Chairman of the Board
Tel Aviv, Israel
August 2, 2013
|
·
|
your spouse, siblings, parents, grandparents, descendants, spouse’s descendants, siblings or parents or the spouses of any of these people (a "
Relative
");
|
·
|
any entity in which you or a Relative of yours hold 5% or more of such entity's outstanding shares or voting rights;
|
·
|
any entity in which you or a Relative of yours is a director or general manager, or in which you or a Relative of yours have the power to appoint one or more directors or the general manager
; and
|
·
|
a person voting under a proxy given by you
.
|
Beneficial Owner
|
Number of Ordinary Shares Beneficially Owned
|
Percent of Ownership
|
||||||
Martin Gerstel
(2)
|
2,437,100 | 6.26 | % | |||||
Anat Cohen-Dayag
(3)
|
686,103 | 1.76 | % | |||||
Directors and other Office Holders as a group (consisting of 14 persons)
(4)
|
4,168,066
|
10.25
|
% |
(a)
|
updating the insurance, indemnification and exemption provisions to reflect recent changes in Israeli law by allowing the Company to insure and indemnify directors and other Office Holders for certain legal fees and expenses and certain payments incurred or imposed in administrative proceedings, as well as allowing insurance, indemnification and release of the Company’s directors and other Office Holders to the fullest extent permitted by law;
|
(b)
|
allowing the Company to convene a general meeting of shareholders without sending notice to the shareholders but rather by publicizing the convening of general meetings in a manner reasonably determined by the Company;
|
(c)
|
clarifying certain notice and publication procedures;
|
(d)
|
clarifying that the Board has the authority (without the need to receive shareholder approval) to determine the remuneration of the Company’s independent auditors, as commonly practiced by companies in Israel and in the United States;
|
(e)
|
clarifying that all resolutions of shareholders, except with respect to those matters which require a special majority under the Companies Law, but including with respect to those matters which require a special majority under the Companies Law due only to the Company's status as a company that was incorporated prior to the effective date of the Companies Law, require a simple majority of the voting power present and voting at any general meeting of shareholders, as the Company has conducted itself to date;
|
(f)
|
providing that certain related party transactions may be approved by committees of the Board if so authorized by the Board; and
|
(g)
|
implementing certain other non-substantive changes to the Articles, including correcting certain linguistic inconsistencies and ambiguities.
|
(a)
|
to ratify and approve the remuneration to be provided to the non-management directors of the Company as described above; and
|
(b)
|
to ratify and approve the purchase and the periodic renewal, at the expense of the Company, without the need for further act or approval, of insurance coverage in respect of the liability of the Company's Office Holders (as such term is defined in the Israel Company Law, 5759-1999), including its directors and its chief executive officer currently in office, and any additional or other Office Holders, including directors or chief executive officer(s) as may be appointed from time to time in the future, including external directors, to the maximum extent permitted by law, that will provide for up to $15 million in coverage and will include coverage with respect to any public offering of shares or other securities of the Company and that each of the chairman of the Company's board of directors and the chief executive officer of the Company as shall be in office from time to time and/or any person designated by him or her, be, and each of them hereby is, authorized to obtain, renew and keep in force and effect such insurance; and
|
(c)
|
to exempt and release to the maximum extent permitted by law all directors of the Company and the chief executive officer of the Company currently in office, and any additional or other directors and chief executive officer(s) as may be appointed from time to time in the future, including external directors, without the need for further act or approval, from and against all liability for monetary or other damages due to, or arising or resulting from, a breach of their duty of care to the Company, including, with respect to directors, in their capacity as officers of the Company to the extent they also serve as officers of the Company, including with respect to any such breach in their capacity as Office Holders of the Company which occurred prior to the date hereof; and
|
(d)
|
that the Company undertake to indemnify all directors and the chief executive officer of the Company currently in office, and any additional or other directors and chief executive officer(s) as may be appointed from time to time in the future, including external directors, without the need for further act or approval, to the extent, for such matters, costs and expenses and as set forth in the form of Indemnification Undertaking and Exemption and Release attached as Exhibit C to the Company's Proxy Statement for its September 2013 Special General Meeting of Shareholders, including with respect to any acts or omissions made in their capacity as Office Holders prior to the date hereof, all subject to and as set forth in said Exhibit C; and
|
(e)
|
to issue letters of indemnification and exemption to all directors and the chief executive officer of the Company currently in office, and to any additional or other directors and chief executive officer(s) as may be appointed from time to time in the future, including external directors, without the need for further act or approval, in the form of Exhibit C to the Company's Proxy Statement for its September 2013 Special General Meeting of Shareholders, and that each of the chairman of the Company's board of directors and the chief executive officer of the Company as shall be in office from time to time and/or any person designated by him or her, be, and each of them hereby is, authorized to execute and deliver any such letters of indemnification and exemption in the name of the Company and on its behalf."
|
(a)
|
to grant to Mr. Martin Gerstel, the Company’s Chairman of the Board of Directors options to purchase 60,000 Ordinary Shares of the Company at an exercise price of $5.445 per share; and
|
(b)
|
to grant to Dr. Anat Cohen-Dayag, the Company’s current chief executive officer options to purchase 120,000 Ordinary Shares of the Company at an exercise price of $5.445 per share.”
|
By Order of the Board of Directors,
/S/ Martin S. Gerstel
Martin S. Gerstel
Chairman of the Board
Tel Aviv, Israel
August 2, 2013
|
1. | Company Name |
2.
|
Purpose
|
3.
|
Interpretation
|
(a)
|
Unless the subject or the context otherwise requires: (i) words and expressions defined in the Companies Law in force on the date when these Articles or any amendment thereto, as the case may be, first became effective shall have the same meanings defined therein; (ii) words and expressions importing the singular shall include the plural and vice versa; (iii) words and expressions importing the masculine gender shall include the feminine gender; and (iv) words and expressions importing persons shall include
bodies
corporate
bodies
.
|
(b)
|
The captions in these Articles are for convenience only and shall not be deemed a part hereof or affect the construction of any provision hereof.
|
c)
|
The specific provisions of these Articles shall supercede the provisions of the Companies Law to the extent permitted under the Companies Law. With respect to any matter that is not specifically addressed in these Articles, the provisions of the Companies Law shall govern.
|
4.
|
Limitation of Liability
|
5.
|
Authorized Share Capital
|
6.
|
Ordinary Shares
|
7.
|
Increase of Share Capital
|
8.
|
Special Rights; Modifications of Rights
|
(a)
|
The Company may, from time to time, provide for shares with such preferred or deferred rights or rights of redemption or other special rights and/or such restrictions, whether in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in the resolution pursuant to which such shares are created.
|
(b)
|
(i) If at any time the share capital is divided into different classes of shares, the rights attached to any class, unless otherwise provided by these Articles, may be modified or abrogated by the Company, subject to the consent in writing of, or sanction of a resolution passed by, the holders of a majority of the issued shares of such class at a separate
General Meeting
general meeting
of the holders of the shares of such class.
(ii) The provisions of these Articles relating to General Meetings shall, mutatis mutandis, apply to any separate
General Meeting
general meeting
of the holders of the shares of a particular class; provided, however, that the requisite quorum at any such separate
General Meeting
general meeting
shall be two or more shareholders present in person or proxy and holding not less than thirty-three and a third percent (331/3%) of the issued shares of such class.
(iii)
Unless otherwise provided by these Articles, the enlargement of an existing class of shares, or the issuance of additional shares thereof, or the creation of a new class of shares identical to an existing class of shares in all respects shall not be deemed, for purposes of this Article 8(b), to modify or abrogate the rights attached to the previously issued shares of such class or of any other class.
|
9.
|
Consolidation, Subdivision, Cancellation and Reduction of Share Capital
|
(a)
|
The Company may, from time to time (subject, however, to the provisions of Article 8(b) hereof and to applicable law):
|
(i)
|
consolidate and divide
all or
any
or all
of its issued or unissued share capital into shares of larger nominal value than its existing shares;
|
(ii)
|
subdivide its shares (issued or unissued) or any of them, into shares of smaller nominal value than is fixed by these Articles (subject, however, to the provisions of the Companies Law), and the resolution whereby any share is subdivided may determine that, as among the holders of the shares resulting from such subdivision, one or more of the shares may, as compared with the others, have any such preferred or deferred rights or rights of redemption or other special rights, or be subject to any such restrictions, as the Company has power to attach to unissued or new shares;
|
(iii)
|
cancel any shares
,
which
,
at the date of the adoption of such resolution have not been taken or agreed to be taken by any person, and diminish the amount of its share capital by the amount of the shares so cancelled; or
|
(iv)
|
reduce its share capital in any manner, subject to any authorization or consent required
,
by law.
|
(b)
|
With respect to any consolidation of issued shares into shares of larger nominal value, and with respect to any other action which may result in fractional shares, the
board of directors of the Company (the "
Board
" or the "
Board of Directors
")
may settle any difficulty which may arise with regard thereto, as it deems fit, including, inter alia, resort to one or more of the following actions:
|
(i)
|
determine, as to the holder of shares so consolidated, which issued shares shall be consolidated into each share of larger nominal value;
|
(ii)
|
allot, in contemplation of or subsequent to such consolidation or other action, such shares or fractional shares sufficient to preclude or remove fractional share holdings;
|
(iii)
|
redeem, in the case of redeemable
preference
shares, and subject to applicable law, such shares or fractional shares sufficient to preclude or remove fractional share holdings;
|
(iv)
|
cause the transfer of fractional shares by certain shareholders of the Company to other shareholders thereof so as to most expediently preclude or remove any fractional shareholdings, and cause the transferees to pay the transferors the fair value of fractional shares so transferred, and the Board of Directors is hereby authorized to act as agent for the transferors and transferees with power of substitution for purposes of implementing the provisions of this sub-Article 9(b)(iv).
|
10.
|
Issuance of Share Certificates; Replacement of Lost Certificates
|
(a)
|
Share certificates shall bear the stamp or seal of the Company and shall bear the
manual or facsimile
signature of a
member of the Board of Directors (a "
Director
")
and/ or of any other person or persons authorized thereto by the Board of Directors.
In the event that any Director or such other authorized person who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such Director or authorized person before such certificate is issued, it may be issued by the Company with the same effect as if it were such Director or authorized person at the date of issue.
|
(b)
|
Each shareholder shall be entitled to one numbered certificate for all the shares of any class registered in his name, and if the Board of Directors so approves, to several certificates, each for one or more of such shares.
|
(c)
|
A share certificate registered in the names of two or more persons shall be delivered to the person first named in the
Share
Register
(as defined in Article 24(a) below)
in respect of such co-ownership
and such delivery shall be deemed sufficient delivery to all co-owners. The Company shall not be obligated to issue more than one share certificate to the joint holders
.
|
(d)
|
If a share certificate is defaced, lost or destroyed, it may be replaced, upon payment of such fee, and upon the furnishing of such evidence of ownership and such indemnity, as the Board of Directors
may think
deem
fit.
|
(a)
|
The Board of Directors may, from time to time, make such calls as it may think appropriate upon shareholders in respect of any sum unpaid in respect of shares held by such shareholders which is not, by the terms of allotment thereof or otherwise, payable at a fixed time, and each shareholder shall pay the amount of every call so made upon him (and of each installment thereof if the same is payable in installments), to the person(s) and at the time(s) and place(s) designated by the Board of Directors, as any such time(s) may be thereafter extended and/or such person(s) or place(s) changed. Unless otherwise stipulated in the resolution of the Board of Directors (and in the notice hereafter referred to), each payment in response to a call shall be deemed to constitute a pro rata payment on account of all shares in respect of which such call was made.
|
(b)
|
Notice of any call shall be given in writing to the shareholder(s) in question not less than fourteen (14) days prior to the time of payment, specifying the time and place of payment, and designating the person to whom such payment shall be made; provided
,
however, that before the time for any such payment, the Board of Directors may, by notice in writing to such shareholder(s), revoke such call in whole or in part, extend such time, or alter such person and/or place. In the event of a call payable in installments, only one notice thereof need be given.
|
(c)
|
If, by the terms of allotment of any share or otherwise, any amount is made payable at any fixed time, every such amount shall be payable at such time as if it were a call duly made by the Board of Directors and of which due notice had been given, and all the provisions herein contained with respect to such calls shall apply to each such amount.
|
(d)
|
The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof and all interest payable thereon.
|
(e)
|
Any amount unpaid in respect of a call shall bear interest from the date on which it is payable until actual payment thereof, at such rate (not exceeding the then prevailing debitory rate charged by leading commercial banks in Israel), and at such time(s) as the Board of Directors may prescribe.
The Board of Directors shall, however, be at liberty to waive the payment of interest, wholly or in part. No shareholder shall be entitled to receive any dividend or to exercise any privileges as a shareholder until th
e
y have paid all calls for the time being due and payable on every share held by them whether alone or jointly with any other person along with interest and expenses, if any.
|
(f)
|
Upon the allotment of shares, the Board of Directors may provide for differences among the allottees of such shares as to the amount of calls and/or the times of payment thereof.
|
15.
|
Prepayment
|
16.
|
Forfeiture and Surrender
|
(a)
|
(a)
If any shareholder fails to pay any amount payable in respect of a call, or interest thereon as provided for herein, on or before the day fixed for payment of the same, the Company, by resolution of the Board of Directors, and subject to the provisions
of Section 181
of the Companies Law, may at any time thereafter, so long as the said amount or interest remains unpaid, forfeit all or any of the shares in respect of which said call had been made. Any expense incurred by the Company in attempting to collect any such amount or interest, including, inter alia, attorneys' fees and costs of
legal
suit, shall be added to, and shall, for all purposes (including the accrual of interest thereon), constitute a part of the amount payable to the Company in respect of such call.
|
(b)
|
(b)
Upon the adoption of a resolution of forfeiture, the Board of Directors shall cause notice thereof to be given to such shareholder, which notice shall state that, in the event of the failure to pay the entire amount so payable within a period stipulated in the notice (which period shall not be less than fourteen (14) days and which may be extended by the Board of Directors), such shares shall be ipso facto forfeited, provided, however, that, prior to the expiration of such period, the Board of Directors may nullify such resolution of forfeiture, but no such nullification shall stop the Board of Directors from adopting a further resolution of forfeiture in respect of the non-payment of the same amount.
|
(c)
|
(c)
Whenever shares are forfeited as herein provided, all dividends theretofore declared in respect thereof and not actually paid shall be deemed to have been forfeited at the same time.
|
|
|
(d) The Company, by resolution of the Board of Directors, may accept the voluntary surrender of any share.
|
(e)
|
Any share forfeited or surrendered as provided herein shall become the property of the Company, and the same, subject to the provisions of these Articles, may be sold, re-allotted or otherwise disposed of as the Board of Directors thinks fit.
|
(f)
|
Any shareholder whose shares have been forfeited or surrendered shall cease to be a shareholder in respect of the forfeited or surrendered shares, but shall, notwithstanding, be liable to pay, and shall forthwith pay, to the Company, all calls, interest and expenses owing upon or in respect of such shares at the time of forfeiture or surrender, together with interest thereon from the time of forfeiture or surrender until actual payment, at the rate prescribed in Article 14(e) above, and the Board of Directors, in its
sole
discretion, may enforce the payment of such moneys, or any part thereof, but shall not be under any obligation to do so. In the event of such forfeiture or surrender, the Company, by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all amounts then owing by the shareholder in question (but not yet due) in respect of all shares owned by such shareholder, solely or jointly with another, and in respect of any other matter or transaction whatsoever.
|
(g)
|
The Board of Directors may at any time, before any share so forfeited or surrendered shall have been sold, re-allotted or otherwise disposed of, nullify the forfeiture or surrender on such conditions as it thinks fit, but no such nullification shall stop the Board of Directors from re-exercising its powers of forfeiture pursuant to this Article 16.
|
17.
|
Lien
|
(a
)
)
|
Except to the extent the same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon all the shares registered in the name of each shareholder (without regard to any equitable or other claim or interest in such shares on the part of any other person), and upon the proceeds of the sale thereof, for such shareholders debts, liabilities and engagements arising from any cause whatsoever, solely or jointly with another, to or with the Company, whether the period for the payment, fulfillment or discharge thereof shall have actually arrived or not. Such lien shall extend to all dividends from time to time declared in respect of such share. Unless otherwise provided, the registration by the Company of a transfer of shares shall be deemed to be a waiver on the part of the Company of the lien (if any) existing on such shares immediately prior to such transfer.
|
(b)
|
The Board of Directors may cause the Company to sell any shares subject to such lien when any such debt, liability or engagement has matured, in such manner as the Board of Directors may think fit, but no such sale shall be made unless such debt, liability or engagement has not been satisfied within fourteen (14) days after written notice of the intention to sell shall have been served on such shareholder, or such shareholder's executors or administrators.
|
(c)
|
(c)
The net proceeds of any such sale, after payment of the costs thereof, shall be applied in or toward satisfaction of the debts, liabilities or engagements of such shareholder (whether or not the same have matured), or any specific part of the same (as the Company may determine), and the residue (if any) shall be paid to the shareholder, such shareholder's executors, administrators or assigns.
|
18.
|
Sale after Forfeiture or Surrender or in Enforcement of Lien
|
19.
|
Redeemable Shares
|
20.
|
Effectiveness and Registration
|
21.
|
of Registration
|
22.
|
Record Date for Notices of General Meetings and Other Action
|
23.
22.
|
Decedents' Shares
|
(a)
|
In case of a share registered in the names of two or more holders, the Company may recognize the survivor(s) as the sole owner(s) thereof unless and until the provisions of Article
23
22
(b) have been effectively invoked.
|
(b)
|
Any person becoming entitled to a share in consequence of the death of any person, upon producing evidence of the grant of probate or letters of administration or declaration of succession (or such other evidence as the Board of Directors may reasonably deem sufficient that he sustains the character in respect of which he proposes to act under this Article or of his title), shall be registered as a shareholder in respect of such share, or may, subject to the regulations as to transfer herein contained, transfer such share.
|
24.
23.
|
Receivers and Liquidators
|
(a)
|
The Company may recognize the receiver or liquidator of any corporate shareholder in winding-up or dissolution, or the receiver or trustee in bankruptcy of any shareholder, as being entitled to the shares registered in the name of such shareholder.
|
(b)
|
The receiver or liquidator of a corporate shareholder in winding-up or dissolution, or the receiver or trustee in bankruptcy of any shareholder, upon producing such evidence as the Board of Directors may deem sufficient that he sustains the character in respect of which he proposes to act under this Article or of his title, shall with the consent of the Board of Directors (which the Board of Directors may grant or refuse in its absolute discretion), be registered as a shareholder in respect of such shares, or may, subject to the regulations as to transfer herein contained, transfer such shares.
|
(a)
|
The Company shall keep a Register (as defined in this Article 24(a)) in which it may record such information as may be deemed appropriate by the Board of Directors and/or as may be permitted by the Companies Law or these Articles. In addition, the Company shall record in the Register the following information:
|
(i)
|
The names and addresses of the shareholders, the number of shares held by each shareholder and the amount paid or the amount to be considered as paid on the shares of each shareholder;
|
(ii)
|
The day each person was registered in the Register as a shareholder;
|
(iii)
|
The amounts called, if any, that are due on the shares of each shareholder; and
|
(iv)
|
Any other information required by the Companies Law or these Articles to be recorded in the Register.
|
(b)
|
The principal register shall be kept at the registered office of the Company for the time being (the "
Office
") and, apart from the times the Register is closed in accordance with the provisions of the Companies Law or these Articles, shall be open to the inspection of any shareholder free of charge, and of any other person at such fee as the Company shall determine for each matter, during regular business hours.
|
(c)
|
The Register may be closed for such period, if any, as the Board of Directors shall determine from time to time, on the condition that the Register shall not be closed for a period exceeding 30 days during any calendar year; and on the additional condition that the Register shall not be closed unless a notice has been published in accordance with the provisions of the Companies Law, if required.
|
25.
|
Annual General Meeting
|
(a)
|
An
Annual
annual
General Meeting shall be held once in every calendar year at such time (within a period of not more than fifteen (15) months after the last preceding
Annual
annual
General Meeting) and at such place either
within or without
in
the State of Israel
or abroad
as may be determined by the Board of Directors
. Such meetings shall be called "
Annual General Meetings
"
.
|
(b)
|
Subject to the provisions of these Articles, the function of the Annual General Meeting shall be to elect the members of the Board of Directors; to receive
the Financial Statements
and consider the profit and loss account, the balance sheet and the ordinary reports and accounts of the Directors and auditors
, to appoint the Company’s auditors and to
fix their remuneration and to
transact any other business which under these Articles or the Companies Law
are to
may
be transacted at a
General Meeting
general meeting of shareholders
.
|
26.
|
Special General Meetings
|
(a)
|
(a) All General Meetings
All general meetings of shareholders of the Company
other than Annual General Meetings shall be called "
Special General Meetings
."
A general meeting of shareholders of the Company whether it is an Annual General Meeting or a Special General Meeting, will be referred to as a "
General Meeting
".
|
(b)
|
(b)
The Board of Directors may, whenever it thinks fit, convene a Special General Meeting at such time and place,
within or out of
in
the State of Israel
or abroad
, as may be determined by the Board of Directors.
|
(c)
|
(c)
The Board of Directors shall be obligated to convene a Special General Meeting
at such time and place, within or without the State of Israel, as may be determined by the Board of Directors
, upon requisition in writing in accordance with the Companies Law
.
, at such time and place,
in the State of Israel or abroad, as may be determined by the Board of Directors. .
|
27.
|
Notice
Convening of General Meetings
; Omission to Give Notice
|
(
c)
|
Notwithstanding anything to the contrary in this Article 27,
b)
Without derogating from the provisions of Article 27(a) above,
and subject to
any
applicable
law and
stock exchange rules
or regulations, notice by the Company of a General Meeting which is published in two daily newspapers in Israel shall be deemed to have been duly given on the date of such publication to any shareholder whose address as listed in the Register of Shareholders (or as designated in writing for the receipt of notices and other documents) is located in the State of Israel, and notice by the Company of a General Meeting which is published in one daily newspaper in New York, New York, U.S.A. or in one international wire service
and regulations, the Company will publicize the convening of General Meetings in any manner reasonably determined by the Company, such as posting a notice on the Company's website, filing an appropriate periodic report with the United State Securities and Exchange Commission (the "
SEC
"), by publishing on one or more international wire services or in one or more newspapers and any such publication
shall be deemed to have been duly
made,
given
on the date of such publication to any shareholder whose address as registered in the Register of Shareholders (or as designated in writing for the receipt of notices and other documents) is located outside Israel.
and delivered to all shareholders on the date on which it is first made, posted, filed or published in the manner so determined by the Company in its sole discretion.
The date of publication
of a notice
in respect
of a General Meeting as set forth in this Article, and the date of the meeting shall be counted as part of the days comprising any notice period with respect to such General Meeting.
|
28.
|
Record Date for General Meetings and Other Action
|
28.
29.
|
Entitlement to Notice;
Participation
|
29.
30.
|
Quorum
|
(a)
|
Two or more shareholders (not in default in payment of any sum referred to in Article
35
37
(a) hereof), present in person, by proxy or by proxy card and holding shares conferring in the aggregate thirty-three and a third percent (
331
33 1
/3%) or more of the voting power of the Company, shall constitute a quorum at General Meetings. No business shall be transacted at a General Meeting, or at any adjournment thereof, unless the requisite quorum is present
when
at the commencement of
the meeting
proceeds to business
.
|
(b)
|
If within
half
an hour from the time appointed for the
meeting
General Meeting
a quorum is not present, the
meeting, if convened upon requisition under Article 26(c), shall be dissolved, but in any other case
General Meeting, if convened by the Board upon the demand of shareholders or upon the demand of less than 50% of the Directors then in office or directly by such shareholders or Directors, shall be cancelled. Otherwise, if a General Meeting is called and no quorum is present within half an hour from the time appointed for such General Meeting,
it shall stand adjourned to the same day in the
next
following
week, at the same time and place
,
or to such
other
day
and at such
,
time and place as the
Chairman may determine with the consent of the holders of a majority of the voting power represented at the meeting in person or by proxy and voting on the question of
Directors may determine and specify in the publication with respect to the General Meeting. It shall not be necessary to give notice of or publicize such
adjournment
.
. No business shall be transacted at any adjourned meeting except business that might lawfully have been transacted at the meeting as originally called. At such adjourned meeting, any two (2) shareholders (not in default as aforesaid) present in person, by proxy or by proxy card, shall constitute a quorum.
|
(c)
|
The Board of Directors may determine,
in
at
its
sole
discretion, the matters that may be voted upon at the meeting by proxy in addition to the matters listed in Section 87(a) of the Companies Law.
|
30.
31.
|
Chairman
|
31.
32.
|
Adoption of Resolutions at General Meetings
|
(a)
|
Except with respect to matters which require the approval of a special majority under the Companies Law
(but including with respect to matters which would require a special majority under the Companies Law due only to the Company's status as a company that was incorporated prior to the effective date of the Companies Law)
, all resolutions of the shareholders shall be deemed adopted if approved by the holders of a simple majority of the voting power represented at the meeting, in person, by proxy or by proxy card, and voting thereon.
|
(b)
|
Every question submitted to a General Meeting shall be decided by a show of hands, but if a written ballot is demanded by any shareholder present in person or by proxy and entitled to vote at the meeting, the same shall be decided by such ballot. A written ballot may be demanded before the proposed resolution is voted upon or immediately after the declaration by the Chairman of the results of the vote by a show of hands. If a vote by written ballot is taken after such declaration, the results of the vote by a show of hands shall be of no effect, and the proposed resolution shall be decided by such written ballot. The demand for a written ballot may be withdrawn at any time before the same is conducted, in which event another shareholder may then demand such written ballot. The demand for a written ballot shall not prevent the continuance of the meeting for the transaction of business other than the question on which the written ballot has been demanded. All votes properly tendered by proxy card, as set forth in Article
33
37
(c)(iii), with respect to a given resolution shall be counted for purposes of determining the outcome of any vote with respect to such resolution taken by show of hands or by
secret
written
ballot.
|
(c)
|
A declaration by the Chairman of the meeting that a resolution has been carried unanimously, or carried by a particular majority, or lost, and an entry to that effect in the minute book of the Company, shall be prima facie evidence of the fact without proof of the number or proportion of the votes recorded in favor of or against such resolution.
|
32.
33.
|
Manner of the Meeting
|
(a)
|
participate in the business for which the meeting has been convened;
|
(b)
|
hear all persons who speak (whether by the use of microphones, loudspeakers audio-visual communications equipment or otherwise) in the principal meeting place and any satellite meeting place(s); and
|
(c)
|
be heard by all other persons so present in the same way.
|
33.
34.
|
Resolutions in Writing
|
34.
35.
|
Power to Adjourn
|
(a)
|
The Chairman of a General Meeting at which a quorum is present may, with the consent of the holders of a majority of the voting power represented in person or by proxy and voting on the question of adjournment (and shall if so directed by the meeting), adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting except business which might lawfully have been transacted at the meeting as originally called.
|
(b)
|
It shall not be necessary to give any notice of an adjournment,
unless
however, if
the meeting is adjourned for thirty (30) days or more
in which event notice thereof shall be given in the manner required for the meeting as originally called
, the Company shall publicize the adjournment and the matters to be included on the agenda of the adjourned General Meeting in the same manner in which it announced the convening of the original General Meeting
.
|
35.
36.
|
Voting Power
|
36.
37.
|
Voting Rights
|
(a)
|
No shareholder shall be entitled to vote at any General Meeting (or be counted as a part of the quorum thereat), unless all calls and other sums then payable by such shareholder in respect of such shareholder's shares in the Company have been paid.
|
(b)
|
A company or other corporate body being a shareholder of the Company may, subject to applicable law, authorize any person to be its representative at any meeting of the Company or execute or deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise on behalf of such shareholder all the power that the latter could have exercised if it were an individual shareholder. Upon the request of the Chairman of the meeting, written evidence of such authorization (in form acceptable to the Chairman) shall be delivered to the Chairman.
|
(c)
|
Any shareholder entitled to vote may vote in one of the following manners:
|
(i)
|
personally;
|
(ii)
|
by proxy (who need not be a shareholder of the Company);
|
(iii)
|
by proxy card, provided it is completed and returned to the Company’s offices in accordance with its terms; or
|
(iv)
|
if the shareholder is a company or other corporate body, by a representative authorized pursuant to Article
36
37
(b).
|
(d)
|
If two or more persons are registered as joint holders of any share, the vote of the senior who tenders a vote, in person, by proxy or by proxy card, shall be accepted to the exclusion of the vote(s) of the other joint holder(s); and for this purpose seniority shall be determined by the order in which the names
stand
appear
in the
Share
Register.
|
37.
38.
|
Proxies; Instrument of Appointment
|
(a)
|
The instrument appointing a proxy shall be in writing and shall be substantially in the following form:
|
(b)
|
The instrument appointing a proxy (and the power of attorney or other authority, if any, under which such instrument has been signed) shall either be delivered to the Company (at its
Registered
Office, or at its principal place of business or at the offices of its registrar and/or transfer agent or at such place as the Board of Directors may specify) not less than
two
twenty four
(
2
24
) hours before the time fixed for the meeting at which the person named in the instrument proposes to vote, or presented to the Chairman at such meeting.
|
(c)
|
Proxy cards shall be in such form, and substance, as shall be prescribed by the Board of Directors. Proxy cards shall be completed and delivered to the Company (at its
Registered
Office, or at its principal place of business or at the offices of its registrar and/or transfer agent or at such place as the Board of Directors may specify) in accordance with its terms.
|
(d)
|
A vote cast pursuant to an instrument appointing a proxy or by proxy card shall be valid notwithstanding the previous death, liquidation or winding-up of the appointing shareholder (or of his attorney-in-fact, if any, who signed such instrument), or the revocation of the appointment or the transfer of the share in respect of which the vote is cast, provided no written intimation of such death, liquidation, winding-up revocation or transfer shall have been received by the Company or by the Chairman of the meeting before such vote is cast and provided, further, that the appointing shareholder, if present in person at said meeting, may revoke the appointment by means of a
writing, oral
written or, verbal
notification to the Chairman, or otherwise.
|
(e)
|
An instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairman
of the meeting
, subsequent to receipt by the Company of such instrument, of written notice signed by the person signing such instrument or by the shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed) or of an instrument appointing a different proxy (and such other documents, if any, required under this Article
37
38
(
b
e
) for such new appointment), provided such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time for delivery of the instrument revoked thereby as referred to in Article
37
38
(
b
e
) hereof, or (ii) if the appointing shareholder is present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairman of such meeting of written notice from such shareholder of the revocation of such appointment, or if and when such shareholder votes at such meeting. A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the revocation or purported cancellation of the appointment, or the presence in person
or vote
of the appointing shareholder at a meeting for which it was rendered, unless such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article
37
38
(
b
e
) at or prior to the time such vote was cast.
|
38.
39.
|
Powers of Board of Directors
|
(a)
|
General
. The Board of Directors shall determine the Company's policies, oversee the activities of the
chief executive officer (the "
Chief Executive Officer
")
, and take such other actions as are described in Section 92 of the Companies Law. The Board of Directors shall be empowered to exercise any power of the Company not conferred
upon
by the Companies Law or by these Articles on any other organ of the Company. The authority conferred on the Board of Directors by this Article
38
39
shall be subject to the provisions of the Companies Law and
of
these Articles.
|
(b)
|
Borrowing Power
. The Board of Directors may from time to time, at its discretion, cause the Company to borrow or secure the payment of any sum or sums of money for the purposes of the Company, and may secure or provide for the repayment of such sum or sums in such manner, at such times and upon such terms and conditions as it deems fit, and, in particular, by the issuance of bonds, perpetual or redeemable debentures, debenture stock, or any mortgages, charges, or other securities on the undertaking or the whole or any part of the property of the Company, both present and future, including its uncalled or called but unpaid capital for the time being.
|
(c)
|
Reserves
. The Board of Directors may, from time to time, set aside any amount(s) out of the profits of the Company as a reserve or reserves for any purpose(s) which the Board of Directors, in its absolute discretion, shall deem fit, including without limitation, capitalization and distribution of bonus shares, and may invest any sum so set aside in any manner and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any such reserve or any part thereof in the business of the Company without being bound to keep the same separate from other assets of the Company, and may subdivide or
redesignate
re-designate
any reserve or cancel the same or apply the funds therein for another purpose, all as the Board of Directors may
deem fit
from time to time
think fit
.
|
39.
40.
|
Exercise of Powers of Directors
|
(a)
|
A meeting of the Board of Directors at which a quorum is present, whether in person or by any other means by which the Directors may hear each other simultaneously, shall be competent to exercise all the authorities, powers and discretions vested in or exercisable by the Board of Directors.
|
(b)
|
A resolution proposed at any meeting of the Board of Directors shall be deemed adopted if approved by a majority of the Directors present
and entitled to vote
when such resolution is put to a vote and voting thereon.
|
(c)
|
The Board of Directors is authorized to adopt any resolution without an actual meeting, provided that all
A resolution in writing signed by all of the Directors or members of a Committee of the Board of
Directors then in office and lawfully entitled to vote thereon (as conclusively determined by the Chairman of the Board of Directors)
or to which all of such Directors
have agreed in writing or given their consent (by
telephone, e-mail, facsimile, letter or otherwise) to the adoption of such resolution. In the event of the adoption of a resolution pursuant to this Article 39(c),
letter, telegram, telex,
facsimile, email or their oral consent by telephone (provided that in such event, a written summary thereof has been approved and signed by
the Chairman of the Board
shall state in the minutes the manner in which each Director voted on the resolution and the fact that all directors consented to the adoption of the resolution without the convening of a meeting.
of Directors of the Company)) shall be deemed to have been unanimously adopted by a meeting of the Board of Directors
or any committee thereof duly convened and held.
|
40.
41.
|
Audit Committee
|
(a)
|
The Board of Directors shall appoint an Audit Committee (all of whose members must be Directors) comprised of at least three Directors, including all of the
Outside
External
Directors. The composition of the Audit Committee shall be in compliance with the Companies Law and with the rules of any stock exchange on which the shares of the Company are traded.
|
(b)
|
The duties of the Audit Committee shall be as provided by applicable law and shall include:
|
(i)
|
to detect any deficiencies in the business management of the Company, by among other things consulting with the Company’s
Internal Auditor
internal auditor
and independent auditors, and to propose to the Board of Directors ways of correcting these deficiencies; and
|
(ii)
|
to decide whether to approve actions and transactions requiring approval of the Audit Committee pursuant to the Companies Law.
|
41.
42.
|
Delegation of Powers
|
(a)
|
Subject to
Section 112 of
the Companies Law, the Board of Directors may delegate any or all of its powers to committees, each consisting of two or more persons (all of whose members must be Directors, at least one of which must be an
Outside Director)
External Director), including the authority to approve transactions that are not "extraordinary transactions" (as defined in the Companies Law), pursuant to Sections 270(1) and 271 of the Companies Law
, and it may from time to time revoke such delegation or alter the composition of any such committee. Any
Committee
committee
so formed (in these Articles referred to as a "Committee of the Board of Directors"), shall, in the exercise of the powers so delegated, conform to any regulations imposed on it by the Board of Directors. The meetings and proceedings of any such Committee of the Board of Directors shall, mutatis mutandis, be governed by the provisions herein contained for regulating the meetings of the Board of Directors, so far as not superseded by any regulations adopted by the Board of Directors under this Article. Unless otherwise expressly provided by the Board of Directors in delegating powers to a Committee of the Board of Directors, such Committee shall not be empowered to further delegate such powers.
|
(b)
|
Without derogating from the provisions of Article
56,
55 below,
the Board of Directors may, subject to the provisions of the Companies Law, from time to time appoint a Secretary to the Company, as well as officers, agents, employees and independent contractors, as the Board of Directors may
think
deem
appropriate, and may terminate the service of any such person. The Board of Directors may, subject to the provisions of the Companies Law, determine the powers and duties, as well as the terms and conditions of employment, of all such persons, and may require security in such cases and in such amounts as it
thinks
deems
appropriate.
|
(c)
|
The Board of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of persons to be the attorney or attorneys of the Company at law or in fact for such purpose(s) and with such powers, authorities and discretions, and for such period and subject to such conditions, as it
thinks
deems
fit, and any such power of attorney or other appointment may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board of Directors may
think
deem
fit, and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions vested in
him
them
.
|
42.
43.
|
Number of Directors
|
(a)
|
The number of
members of the Board of
Directors (including
Outside
External
Directors) shall be determined, from time to time, by the Annual General Meeting, provided that the Board of Directors of the Company shall consist of
not
no
less than five (5)
directors
Directors
and
not
no
more than fourteen (14) Directors.
|
(b)
|
The requirements of the Companies Law applicable to
Outside
External
Directors shall prevail over the provisions of these Articles to the extent that these Articles are inconsistent with the Companies Law, and shall apply to the extent that these Articles are silent.
|
43.
44.
|
Election, Appointment and Removal of Directors
|
(a)
|
The Directors shall be elected and dismissed by
the holders of
a
simple
majority of the
shares
voting power
present and voting at an Annual General Meeting, provided
however
that any vote to appoint or dismiss an
Outside
External
Director shall
be in accordance with and
satisfy the requirements of
Section 239 or Section 246, as the case may be, of
the Com
p
anies Law. Subject to
the maximum number of Directors provided for in
Article
42
43
above, between
annual meetings
Annual General Meetings
, the Board
of Directors
shall be empowered to appoint
directors
Directors
, other than
Outside
External
Directors, by a majority vote of the
directors
Directors then in office
.
|
(b)
|
All
Directors
elected at an Annual General Meeting
, except
Outside
External
Directors, shall
retire at
hold office until the end of
the Annual General Meeting
of the Company
,
immediately following the Annual General Meeting at which they were elected
, subject to the provisions of sub-article 43(d) below. The term of office of Outside
and until their successors have been duly elected or until any such Directors' term of office terminates as provided in the Companies Law or due to any of the circumstances set forth in Article 47 below. Directors appointed by the Board pursuant to Article 44(a) above, shall hold office until the end of the immediately following Annual General Meeting or until such Directors' term of office terminates as provided in the Companies Law or due to any of the circumstances set forth in Article 47 below. The term of office of External
Directors shall be
in accordance with and
as provided in the Companies Law.
|
(c)
|
A retiring Director shall be eligible for re-election, provided that Outside Directors shall only be entitled to re-election as provided in the Companies Law.
Subject to applicable law, a Director who has ceased to hold office shall be eligible for re-election or re-appointment.
|
(d)
|
If at any Annual General Meeting, the places of the vacating directors are not filled, the meeting shall stand adjourned until the same day in the next week at the same time and place, and if at the adjourned meeting the places of the vacating Directors are, again, not filled, the vacating Directors shall be deemed to have been re-elected at the adjourned meeting. In any event, a retiring director shall remain in office until a new director has been elected or appointed in his or her place.
|
(d)
|
The term of office of a Director (including an External Director) will begin as of the date of the Annual General Meeting at which he was elected or as of the date of the meeting of the Board of Directors at which he was appointed (if appointed by the Board pursuant to Article 44(a) above) or at such later date as is determined in the resolution electing or appointing him or pursuant thereto.
|
(e)
|
Notwithstanding anything to the contrary in this Article
43,
44,
the shareholders may, at any time, by
a
resolution
adopted by a simple majority of the voting power present and voting
at a Special General Meeting, discharge from office any
member of the Board of Directors (provided that with respect to Outside Directors, the dismissal is effected in accordance with Section 246 of the Companies Law) and/or to
Director, provided such Director is given a reasonable opportunity to state his or her case before the shareholders at the General Meeting and/or
appoint a
member to the Board of Directors
Director
(provided that with respect to
Outside
External
Directors, the requirements of
Section 239 of
the Companies Law are satisfied).
|
44.
45.
|
Qualification of Directors
|
45.
46.
|
Continuing Directors in the Event of Vacancies
|
46.
47.
|
Vacation of Office
|
(a)
|
The office of a Director shall be vacated by the Director's written resignation. Such resignation shall become effective on the date fixed therein, or upon the delivery thereof to the Company, whichever is later.
|
(b)
|
The Company
will
shall
be entitled, at any time,
by resolution of the shareholders at a Special General Meeting,
to discharge from office any Director
, provided such Director is given a reasonable opportunity to state his or her case before the shareholders at the General Meeting. The power granted by this sub-article shall not apply to Outside Directors, unless such discharge is effected in accordance with Section 246 of the Companies Law.
subject to and in accordance with Article 44(e),
|
(c)
|
The office of a Director shall be vacated, ipso facto, upon the occurrence of any of the following: (i)
such Director's death, (ii) such Director is convicted of a crime as described in Section 232 of the Companies Law, (iii) such Director is removed by a court of law in accordance with Section 233 of the Companies Law, (iv) such Director becomes legally incompetent, or (v) such Director is declared bankrupt, or (vi) if such Director is a corporate entity, upon its winding-up liquidation, whether voluntary or involuntary.
his death, or, if the Director is a legal entity, it has adopted a resolution of voluntary liquidation or winding-up, or a liquidation order has been issued with respect thereto; (ii) should he be declared to be legally incompetent; (iii) should he be declared bankrupt; (iv) should he resign his office by notice in writing to the Company; or (v) as otherwise provided in the Companies Law.
|
47.
48.
|
Remuneration of Directors
|
48.
49.
|
Conflict of Interests
|
49.
|
Intentionally left blank.
|
50.
|
Intentionally left blank.
|
51.
50.
|
Meetings
|
(a)
|
The Board of Directors shall convene meetings as required to fulfill the needs of the Company, but in any event shall convene at least one meeting in every three month period. The Board of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Directors
think
deem
fit. Meetings of the Board of Directors may be held telephonically or by any other means of communication provided that each Director participating in such meeting can hear
and be heard by
all of the other Directors participating in such meeting.
|
(b)
|
The Chairman of the Board of Directors may convene a meeting of the Board of Directors, but not less than
two (2) days' written
twenty four (24) hours
notice shall be given of any meeting, unless such notice is waived in writing by all of the Directors as to a particular meeting. The notice of meeting shall include the agenda of the meeting. Notice of the meetings of the Board of Directors
shall
may be given orally, by telephone, or
be sent to each Director in any
other
reasonable manner at the last physical or email address or telephone or facsimile number that the Director provided to the Company.
|
(c)
|
Upon the receipt of a written request under any of the following circumstances, the Chairman of the Board of Directors shall, and in the absence of a Chairman, any Director receiving such written request shall, convene a meeting of the Board of Directors, but not less than
two (2) days' written
twenty four (24) hours
notice
as aforesaid
shall be given of any meeting, unless such notice is waived in writing by all of the Directors as to a particular meeting:
|
(i)
|
upon the receipt of a written request from any two Directors, or in the event that there are five or less Directors serving in office at the time, upon the written request of any Director;
|
(ii)
|
upon the receipt of a written request from any Director requesting that a meeting be
adjourned
convened
and stating that he or she has learned of an alleged violation of the law or
of
proper business procedure by the Company.
|
(iii)
|
upon the receipt of any written request from the Chief Executive Officer of the Company requesting an action of the Board of Directors; or
|
(iv)
|
upon the receipt of a written
request
notice
from the independent auditor(s) of the Company regarding material flaws in the oversight of the Company's internal accounting methods.
|
52.
51.
|
Quorum
|
(a)
|
Until otherwise unanimously decided by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted by the presence, in person, or by telephone conference of a majority of the Directors then in office who are lawfully entitled to participate
and vote
in the meeting (as conclusively determined by the Chairman of the Board of Directors).
|
(b)
|
If within an hour from the time appointed for the meeting a quorum is not present, the meeting shall stand adjourned to such time, date and place as the Chairman may determine, provided that
not less than two (2) days' written
prior
notice
as aforesaid
shall have been provided to each of the Directors of such meeting. No business shall be transacted at any adjourned meeting except business that might lawfully have been transacted at the meeting as originally called. At such adjourned meeting, any two (2)
members
Directors
present in person shall constitute a quorum.
|
(c)
|
Notwithstanding anything to the contrary in this Article
52,
51,
the quorum for purposes of discussing and resolving upon the termination or suspension of the services of the
Internal Auditor
internal auditor
of the Company shall be a majority of the Directors then in office.
|
53.
52.
|
Chairman of the Board of Directors
|
54.
53.
|
Validity of Acts Despite Defects
|
55.
54.
|
Minutes
|
(a)
|
Minutes of each General Meeting and of each meeting of the Board of Directors (or any committee thereof) shall be recorded and duly entered in books provided for that purpose and shall be held by the Company at its principal place of office or its
Registered
Office or such other place as shall have been determined by the Board of Directors. Such minutes shall, in all events, set forth the names of the persons present at the meeting and all resolutions adopted thereby.
|
(b)
|
Any minutes as aforesaid, if purporting to be signed by the chairman of the meeting or by the chairman of the next succeeding meeting, shall constitute prima facie evidence of the matters recorded therein.
|
56.
55.
|
Chief Executive Officer
|
(a)
|
The Board of Directors shall from time to time appoint one or more persons, whether or not Directors, as Chief Executive Officers(s) of the Company and may confer upon such person(s), and from time to time modify or revoke, such title(s) (including General Manager, Managing Director, Director General or any similar or dissimilar title). The appointment of the Chief Executive Officer(s) may be either for a fixed term or without any limitation of time. The Board of Directors may from time to time remove or dismiss the Chief Executive Officer(s) from office and appoint another or others in the Chief Executive Officer(s)'s place.
|
(b)
|
The Chief Executive Officer(s) shall manage the business of the Company, subject to the policies established by the Board of Directors, such limitations and restrictions as are set forth in these Articles or as the Board of Directors may from time to time prescribe, and the provisions of the Companies Law.
|
(c)
|
The Board of Directors may from time to time determine the Chief Executive Officer(s) salary and other terms and conditions of the Chief Executive Officer's employment, subject to the provisions of the Companies Law.
|
(d)
|
Subject to the provisions of the Companies Law and provided the Board of Directors has authorized him or her to do so, the Chief Executive Officer of the Company may appoint additional Officer Holders (as such term is defined in the Companies Law) of the Company (other than Directors and Chief Executive Officers), and determine the duties and powers of such Office Holders, and the terms and conditions of such Office Holders' employment. The Chief Executive Officer shall notify the Board of Directors of each such appointment at the first meeting of the Board of Directors following such appointment.
|
57.
56.
|
Internal Auditor
|
58.
57.
|
Indemnity and Insurance
|
58.1
57.1
|
Insurance
:
.
Subject to the provisions of
any
the Companies
Law, the Company may enter into
a contract
contracts
to insure
against
the liabilities of its Office Holders for
an obligation imposed on an Office Holder in consequence of an act done by the Office Holder in his capacity as an
any liabilities or expenses incurred by or imposed upon them arising from or as a result of any act (or omission) carried out by them as
Office
Holder
Holders
of the Company
, in
,
to the fullest extent permitted by law, including in respect of any liability imposed on any Office Holder with respect to
any of the following
cases
:
|
(a)
|
A breach of the duty of care owed to the Company or to any other person;
|
(b)
|
A breach of the
fiduciary
duty
of loyalty
owed to the Company, provided that, the Office Holder acted in good faith and had reasonable grounds to assume that such act would not
injure
prejudice the interests of
the Company;
|
(c)
|
A monetary liability
Monetary liabilities or obligations
imposed on him in favor of another person;
|
(d)
|
A payment which the Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israel Securities Law, 5728-1968 (the "
Securities Law
") and expenses that the Office Holder incurred in connection with a proceeding under Chapters H'3, H'4 or I'1 of the Securities Law, including reasonable litigation expenses, including attorney's fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law;
|
(e)
|
Expenses incurred by the Office Holder in connection with a proceeding under Chapter G'1, of the Israel Restrictive Trade Practices Law, 5748-1988 (the "
Restrictive Trade Law
"), including reasonable litigation expenses, including attorney's fees.
|
58.2
57.2
|
Indemnification
. Subject to the provisions of the Companies Law,
including the receipt of all approvals as required therein or under any other applicable Law,
the Company may indemnify any of its Office Holders
for all liabilities and expenses incurred by them arising from or as a result of any act (or omission) carried out by them as Office Holders of the Company and which is indemnifiable pursuant to applicable law,
to the fullest extent permitted by
the Companies Law
law, including,
as follows:
|
(a)
|
retrospectively; and
|
(b)
|
undertake in advance to indemnify the Office Holders
with respect to liabilities or expenses, imposed on such Officer or incurred by him in consequence of an act which he has performed by virtue of being an Officer, as listed below
to the fullest extent permitted by law, including, as follows
:
|
(i)
|
A
f
or any
monetary
obligation
liabilities or obligations
imposed on the Office Holder in favor of another person pursuant to a
court
judgment, including a
compromise
judgment
given in settlement
or
a court-approved arbitration award, provided that the undertaking to indemnify will be limited to: (1) those categories of events which the Board resolves that in its opinion can be foreseen at the time the undertaking to indemnify is given in light of the Company’s then current activities; and (2) such amounts or criteria which the Board sets as reasonable under the circumstances;
an arbitrator's decision approved by a court
;
;
|
(ii)
|
for any payments which the Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities Law and expenses the Office Holder incurred in connection with a proceeding under Chapters H'3, H'4 or I'1 of the Securities Law, including reasonable litigation expenses, including attorney's fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law;
|
(
ii
iii
)
|
Reasonable
f
or reasonable
litigation expenses, including attorney’s
legal
fees,
actually paid
incurred
by the Office Holder in consequence of an investigation or proceeding instituted against the Office Holder by an authority that is authorized to conduct such investigation or proceeding, and
that resulted
which was concluded
without filing
of
an indictment against the Office Holder and without imposing on the Office Holder a financial obligation in lieu of criminal proceedings, or
that resulted
which was concluded
without filing
of
an indictment against the Office Holder but with imposing on such Office Holder a financial obligation in lieu of criminal proceedings in respect of an offense that does not require
the
proof of criminal intent
or in connection with a financial sanction
;
|
(iii)
|
Reasonable litigation costs, including attorney’s legal fees incurred by the Office Holder or which the Office Holder is ordered to pay by a court, in a proceeding filed against the Office Holder by the Company or on its behalf or by another person, or in a criminal charge of which the Office Holder is acquitted, or in a criminal charge of which the Office Holder is convicted of an offense that does not require proof of criminal intent.
|
(iv)
|
for reasonable litigation expenses, including attorney’s fees, incurred by the Office Holder or which the Office Holder is ordered to pay by a court, in a proceeding filed against the Office Holder by the Company or on its behalf or by another person, or in a criminal action of which the Office Holder is acquitted, or in a criminal action in which the Office Holder is convicted of an offense that does not require proof of criminal intent.
|
(v)
|
for expenses incurred by the Office Holder in connection with a proceeding under Chapter G'1, of the Restrictive Trade Law, including reasonable litigation expenses, including attorney's fees.
|
(vi)
|
for any other liability, obligation or expense indemnifiable or which may from time to time be indemnifiable by law.
|
58.3
57.3
|
Exemption of Office Holders
. Subject to the provisions of the Companies Law, the Company may
,
to the fullest extent permitted by law,
exempt
and release
its Office Holders
, including
in advance
for
,
from and against
all or
any
part
of such Office Holders’ liability for
damage in consequence of a breach of the duty of care vis-à-vis the Company, other than for
monetary or other damages due to, or arising or resulting from,
a breach of
their
duty of care
stemming from a Distribution (as such term is defined in the Companies Law) and for a willful or reckless breach of duty of care, excluding a breach of duty of care due to negligence
to the Company..
The Directors of the Company are released and exempt from any and all liability as aforesaid to the fullest extent permitted by law with respect to any such breach, which has been or may be committed
.
|
58.4
57.4
|
The provisions of this Article
58
57
are not intended, and shall not be interpreted so as to restrict the Company, in any manner, in respect of the procurement of insurance and/or indemnification and/or exculpation, in
favour
favor
of any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company who is not an Office Holder.
|
57.5
|
The Company may, as aforesaid, indemnify, insure and exempt from liability any Office Holder to the fullest extent permitted by applicable law. Accordingly: (i) any amendment to the Companies Law, the Securities Law, the Restrictive Trade Law or any other applicable law expanding the ability of the Company to indemnify, insure or exempt from liability any Office Holder, or expanding the right of any Office Holder to be indemnified, insured or exempted from liability, beyond or in addition to the provisions of these Articles, shall, to the fullest extent possible, automatically and immediately apply to the Office Holders of the Company and be deemed as included in these Articles to the fullest extent permitted by applicable law; and (ii) any amendment to the Companies Law, the Securities Law, the Restrictive Trade Law or any other applicable law adversely affecting the ability of the Company to indemnify, insure or exempt from liability any Office Holder or adversely affecting the right of any Office Holder to be indemnified, insured or exempted from liability as provided for in these Articles shall have no effect post factum and shall not affect the Company's obligations or ability to indemnify, insure or exempt from liability an Office Holder for any act (or omission) carried out prior to such amendment, unless otherwise provided by applicable law.
|
59.
58.
|
Rights of Signature and Rubber Stamp
|
(a)
|
The Board of Directors shall be entitled to authorize any person or persons (who need not be Directors) to act and sign on behalf of the Company
and to further delegate such signatory powers
, and the acts and
signature
signatures
of such person(s) on behalf of the Company,
together with the Company's rubber stamp or the Company's name in print or handwriting,
shall bind the Company insofar as such person(s) acted and signed within the scope of such person's authority.
|
|
(b) The Company shall have at least one official rubber stamp.
|
60.
59.
|
Declaration of Dividends
|
(a)
|
Subject to the Companies Law, the Board of Directors may from time to time declare, and cause the Company to pay, such dividends as may appear to the Board of Directors to be justified by the profits of the Company. Subject to the Companies Law, the Board of Directors shall determine the time for payment of such dividends and the record date for determining the shareholders entitled thereto.
|
61.
60.
|
Amount Payable by Way of Dividends
|
(a)
|
Subject to the provisions of these Articles and subject to any rights or conditions attached at that time to any share in the capital of the Company granting preferential, special or deferred rights or not granting any rights with respect to dividends, the profits of the Company which shall be declared as dividends shall be distributed according to the proportion of the nominal value paid up
or credited as paid up
on account of the shares held at the date so appointed by the Company
and in respect of which such dividend is being paid
, without regard to the premium paid in excess of the nominal value, if any. No amount paid or credited as paid on a share in advance of calls shall be treated for purposes of this Article as paid on a share.
|
|
(b) No dividend shall carry interest
as
against the Company.
|
62.
61.
|
Payment in Specie
|
(a)
|
A dividend may be paid, wholly or partly, by the distribution of specific assets of the Company or by the distribution of specific assets, paid-up shares, debentures or debenture stock of any other company, or in any one or more such ways.
|
(b)
|
Upon the determination of the Board of Directors, the Company (i) may cause any monies, investments, or other assets forming part of the undivided profits of the Company, standing to the credit of a reserve fund, or to the credit of a reserve fund for the redemption of capital, or in the hands of the Company and available for dividends, or representing premiums received on the issuance of shares and standing to the credit of the share premium account, to be capitalized and distributed among such of the shareholders as would be entitled to receive the same if distributed by way of dividend and in the same proportion, on the footing that they become entitled thereto as capital, or may cause any part of such capitalized fund to be applied on behalf of such shareholders in paying up in full, either at par or at such premium as the resolution may provide, any unissued shares or debentures or debenture stock of the Company which shall be distributed accordingly or in payment, in full or in part, of the uncalled liability on all issued shares or debentures or debenture stock if such liability exists, on a pro rata basis; and (ii) may cause such distribution or payment to be accepted by such shareholders in full satisfaction of their interest in the said capitalized sum.
|
63.
62.
|
Implementation of Powers under Articles
61
60 and
62
61
|
64.
63.
|
Deductions from Dividends
|
65.
64.
|
Retention of Dividends
|
(a)
|
The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share on which the Company has a lien, and may apply the same in or toward satisfaction of the debts, liabilities, or engagements in respect of which the lien exists.
|
(b)
|
The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share in respect of which any person is, under
these
Articles
23 or 24,
,
entitled to become a shareholder, or which any person is, under
said
these
Articles, entitled to transfer, until such person shall become a shareholder in respect of such share or shall transfer the same.
|
66.
65.
|
Unclaimed Dividends
|
67.
66.
|
Mechanics of Payment
|
68.
67.
|
Receipt from a Joint Holder
|
69.
68.
|
Books of Account
|
70.
69.
|
Fiscal Year
|
71.
70.
|
Audit
|
72.
71.
|
Auditors
|
(a)
|
The shareholders of the Company shall appoint an independent auditor(s) of the Company at the Annual General Meeting. Such appointment shall be in force until the end of the fiscal year for which the appointment is made, or for a longer period if so resolved at the Annual General Meeting, but in no event for a period of more than three fiscal years. The shareholders of the Company may remove the independent auditor(s) at any time.
|
(b)
|
The appointment, authorities, rights and duties of the independent auditor(s) of the Company shall be regulated by applicable law.
|
(c)
|
The Board of Directors shall determine the remuneration of the independent auditor(s),
or shall delegate such authority to the Audit Committee,
and shall report to the shareholders on such remuneration at the Annual General Meeting.
|
73.
72.
|
Donations
|
74.
73.
|
Notices
|
(a)
|
Any written
Without derogating from Article 27 above or Article 73(j) below, any
notice or
other
document may be served by the Company upon any shareholder personally or by sending it by mail addressed to such shareholder at such shareholder's address as described in the
Share
Register or such other address as such shareholder may have designated in writing for the receipt of notices and
other
documents. Any
written
notice or
other
document may be served by any shareholder upon the Company by tendering the same in person to the Secretary or the Chief Executive Officer of the Company at the
principal office of the Company
Office
or by sending it by prepaid registered mail (airmail if posted outside Israel) to the Company at its
Registered Address
Office
. Any such notice or
other
document shall be deemed to have been served two (2) business days after it has been posted (five (5) business days if sent to a place not located on the same continent as the place from where it was posted), or when actually received by the addressee if sooner than two (2) days or five (5) days, as the case may be, after it has been posted, or when actually tendered in person, to such shareholder (or to the Secretary or the Chief Executive Officer); provided
,
however, that notice may be sent by e-mail, facsimile or other electronic means and confirmed by registered mail as aforesaid, and such notice shall be deemed to have been given twenty-four (24) hours after such e-mail, facsimile or other electronic communication has been sent or when actually received by such shareholder (or by the Company), whichever is earlier. If a notice is, in fact, received by the addressee, it shall be deemed to have been duly served, when received, notwithstanding that it was defectively addressed or failed, in some respect, to comply with the provisions of this Article
74
73
(a).
|
(b)
|
All notices to be given to the shareholders shall, with respect to any share to which persons are jointly entitled, be given to whichever of such persons is named first in the
Share
Register, and any notice so given shall be sufficient notice to the holders of such share.
|
(c)
|
(c)
If requested by the Company, each shareholder shall provide the Company with the shareholder's full street and mailing address, as well, if available, with facsimile number and email address.
Any
Without derogating from Article 27 above, any
shareholder whose address is not described in the
Share
Register, and who shall not have designated in writing an address for the receipt of notices, shall not be entitled to receive any notice from the Company.
|
(d)
|
The Company may declare that any document(s) will be delivered or be available for review at the Office or any other place designated by the Board of Directors.
|
(e)
|
Whenever it is required to give prior notice or publicize a specified number of days in advance or where a notice or publication is valid for a specified period, the day of the publication or the day of service of the notice shall be included in such count or period.
|
(f)
|
Service of notice to a relative of a shareholder living at the same address with him will be deemed service to such shareholder.
|
(g)
|
Subject to applicable law, any shareholder, Director or other person entitled to receive notice in accordance with these Articles or law may waive notice, in advance or retroactively, in a particular case or type of case or generally, and if so, notice will be deemed as having been duly served, and all proceedings or actions for which the notice was required will be deemed valid
.
|
(h)
|
Any person entitled to a share by operation of law or by transfer, transmission or otherwise will be bound by any notice served or by any publication made pursuant to these Articles with respect to such share prior to his being registered in the Register as owner of the shares.
|
(i)
|
It shall not be necessary to set forth in detail in any publication as provided for in Article 27(b) above, the full text of any proposed resolutions and a general description of the nature of the matters on the agenda will suffice. The Company shall be entitled, however, but shall be under no obligation to do so, to specify in any publication in respect of a meeting, a place and a time where and when the full text of proposed resolution(s) may be reviewed.
|
(j)
|
Notwithstanding anything to the contrary contained herein, the Company may give notice to any shareholder by posting a notice on the Company's website, filing an appropriate periodic report with the SEC, by publishing on one or more international wire services or in one or more newspapers or by publicizing in any other manner reasonably determined by the Company and the date of such posting, filing or other publication shall be deemed the date on which such notice has been served upon such shareholder. Where notice is given by more than one method, it will be deemed served on the earliest of such dates.
|
(k)
|
The accidental omission to give notice to any shareholder pursuant to any applicable law or these Articles or the non-receipt of any such notice by any shareholder entitled to receive notice shall not invalidate any action, transaction, resolution or proceedings taken by the Company and/or at or by any General Meeting
.
|
75.
74.
|
Winding Up
|
1.
|
General
|
2.
|
Philosophy and Objectives
|
·
|
Improve business results and strategy implementation, and support the Company’s work-plans, from a long-term perspective.
|
·
|
Incentivize Office Holders to create long-term economic value for the Company.
|
·
|
Create a clear line-of-sight between officers’ compensation and both Company-wide and individual performance.
|
3.
|
Officers’ Compensation Package Components
|
a.
|
Base Salary
|
b.
|
Cash Bonuses
|
c.
|
Equity-based Compensation
|
d.
|
Benefits and Perquisites
|
e.
|
Termination Payments
|
3.1.
|
Determining Officers’ Compensation
|
·
|
The officer’s position, scope of responsibility and business challenges.
|
·
|
The officer’s skills, professional experience, education and qualifications.
|
·
|
The officer’s performance results and accomplishments.
|
·
|
The officer’s previous compensation arrangements and seniority.
|
·
|
Paying officers equitably relative to one another based on their position, responsibilities, location, education, experience, qualifications, performance results and accomplishments.
|
·
|
The relationship between the officer’s compensation package and the compensation of the Company’s other employees (including those employed by manpower contractors) and specifically the median and average compensation and the effect of such relationship on work relations in the Company.
|
3.2.
|
Base Salary
|
3.3.
|
Cash Bonuses
|
3.3.1.
|
Annual
Cash Bonuses
|
3.3.2.
|
Ad Hoc and Special Cash
Bonuses
|
3.3.2.1.
|
Ad Hoc Cash Bonuses
|
3.3.2.2.
|
Special Cash Bonuses
|
3.3.2.3.
|
Cap
|
3.4.
|
Equity-based Compensation
|
3.5.
|
Benefits and Perquisites
|
3.6.
|
Termination Payments
|
·
|
Notice period
: advance notice of termination period, not to exceed 3 months, or with respect to the CEO, the Active Chairman and any other Management Directors, if any, 6 months. During the notice period, officers will be entitled to full compensation, including benefits, and will be required to continue work, at the discretion of the Company. The Company may waive an officer’s services during the advance notice period and pay the officer in lieu thereof, including the value of benefits.
|
·
|
Change of Control
: change of control events, such as mergers and acquisitions, may expose the Company and its officers to a great deal of uncertainty. By providing its officers with compensation in events of change of control, the Company reduces to some extent the personal uncertainty of its officers, and thus promotes full and impartial consideration of change of control opportunities. In light of the above, the Company may provide for the payment of up to 6 monthly base salaries to officers in the event their service or employment is terminated during the first year following a pre-defined change of control event, including in the event of voluntarily termination.
|
·
|
Severance payment
: the greater of the amount of severance pay payable pursuant to the Israeli Severance Pay Law, 5723-1963, had the officer been entitled to severance pay pursuant to such law, and the amount accumulated in an officer’s pension fund and/or managers insurance and/or provident fund.
|
·
|
Discretionary (including adaptation) payments
: in special cases, up to 3 monthly base salaries
, or with respect to the CEO, the Active Chairman and any other Management Directors, if any,
6 monthly base salaries.
|
4.
|
Non-management Directors
|
a.
|
Annual Fee
: up to twice the maximum amount but not less than the minimum amount permitted from time to time with respect to the Company in accordance with the Compensation Regulations and subject to the rules set forth therein.
|
b.
|
Per-meeting Fee
: up to twice the maximum amount but not less than the minimum amount permitted from time to time with respect to the Company in accordance with the Compensation Regulations and subject to the rules set forth therein.
|
c.
|
Fixed Annual Equity Grant
: annual equity-based grant, with respect to a fixed number of shares of the Company and/or with a fixed value at grant. Such annual equity-based grant is intended to align Non-management Directors’ interests with the long-term interests of the Company’s shareholders. Equity-based grants shall be pursuant to the Company’s 2010 Share Incentive Plan and/or any other equity-based incentive plan that the Company may adopt in the future, subject to availability thereunder and generally on the terms provided for therein. Until otherwise determined, and to the extent legally available and applicable, equity-based awards to Non-management Directors will be granted through a trustee pursuant to the provisions of Section 102 of the Income Tax Ordinance, under the capital gains route.
|
5.
|
D&O Insurance, indemnification and release
|
6.
|
Recoupment and reduction of Compensation
|
6.1.
|
Clawback
|
6.2.
|
Reduction of Compensation
|
Very truly yours,
Compugen Ltd.
By: ______________________
Title: ______________________
Date: ___________, 2013
|
|
1.
|
Negotiations, execution, delivery and performance of agreements on behalf of the Company including, inter alia, any claim or demand made by a customer, supplier, contractor or other third party transacting any form of business with the Company, relating to the negotiations or performance of such transactions, representations or inducements provided in connection thereto or otherwise.
|
|
2.
|
Any claim or demand made related to anti-competitive acts and acts of commercial wrongdoing.
|
|
3.
|
Any claim or demand made related to acts in regard of invasion of privacy including with respect to databases and acts in regard of slander.
|
|
4.
|
Any claim or demand made for actual or alleged infringement, misappropriation or misuse of any third party’s intellectual property rights including, but not limited to confidential information, patents, copyrights, design rights, service marks, trade secrets, copyrights, misappropriation of ideas by the Company.
|
|
5.
|
Actions taken in connection with the intellectual property of the Company and its protection, including the registration or assertion of rights to intellectual property and the defense of claims relating thereof.
|
|
6.
|
Participation and/or non-participation at the Company’s board meetings, bona fide expression of opinion and/or voting and/or abstention from voting at the Company’s board meetings.
|
|
7.
|
Approval of corporate actions including the approval of the acts of the Company’s management, their guidance and their supervision.
|
|
8.
|
Actions concerning the approval of transactions of the Company with officers and/or directors and/or holders of controlling interests in the Company, and any other transactions referred to in Sections 267A and/or 270 of the Companies Law.
|
|
9.
|
Claims of failure to exercise business judgment and a reasonable level of proficiency, expertise and care in regard of the Company’s business.
|
|
10.
|
Violations of securities laws of any jurisdiction, including without limitation, fraudulent disclosure claims, failure to comply with the United States Securities and Exchange Commission and/or the Israeli Securities Authority and/or any stock exchange disclosure or other rules and any other claims relating to relationships with investors, shareholders and the investment community and any claims related to the Sarbanes-Oxley Act of 2002, as amended from time to time.
|
|
11.
|
Any claim or demand made under any securities laws or by reference thereto, or related to the failure to disclose any information in the manner or time such information is required to be disclosed pursuant to such laws, or related to inadequate or improper disclosure of information to shareholders, or prospective shareholders, or related to the purchasing, holding or disposition of securities of the Company or any other investment activity involving or affected by such securities, including any actions relating to an offer or issuance of securities of the Company to the public by prospectus or privately by private placement, in Israel or abroad, including the details that shall be set forth in the documents in connection with execution thereof.
|
|
12.
|
Actions in connection with the financial statements and/or reports of the Company, including the preparation thereof.
|
|
13.
|
Violations of laws requiring the Company to obtain regulatory and governmental licenses, permits and authorizations or laws related to any governmental grants in any jurisdiction.
|
|
14.
|
Claims in connection with publishing or providing any information, including any filings with any governmental authorities, on behalf of the Company in the circumstances required under any applicable laws.
|
|
15.
|
Any claim or demand made by employees, consultants, agents or other individuals or entities employed by or providing services to the Company relating to compensation owed to them or damages or liabilities suffered by them in connection with such employment or service.
|
|
16.
|
Resolutions and/or actions relating to employment matters of the Company.
|
|
17.
|
Events, pertaining to the employment conditions of employees and to the employer - employee relations, including the promotion of workers, handling pension arrangements, insurance and saving funds, options and other benefits.
|
|
18.
|
Any claim or demand made by any lenders or other creditors or for moneys borrowed by, or other indebtedness of, the Company.
|
|
19.
|
Any claim or demand made by any third party suffering any personal injury and/or bodily injury and/or property damage to business or personal property through any act or omission attributed to the Company, or their respective employees, agents or other persons acting or allegedly acting on their behalf.
|
|
20.
|
Any claim or demand made directly or indirectly in connection with complete or partial failure, by the Company thereof, or their respective directors, officers and employees, to pay, report, keep applicable records or otherwise, of any foreign, federal, state, country, local, municipal or city taxes or other compulsory payments of any nature whatsoever, including without limitation, income, sales, use, transfer, excise, value added, registration, severance, stamp, occupation, customs, duties, real property, personal property, capital stock, social security, unemployment, disability, payroll or employee withholding or other withholding, including any interest, penalty or addition thereto, whether disputed or not.
|
|
21.
|
Any claim or demand made by purchasers, holders, lessors or other users of products or assets of the Company, or individuals treated with such products, for damages or losses related to such use or treatment.
|
|
22.
|
Any administrative, regulatory or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance or violation by any governmental entity or other person alleging potential responsibility or liability (including potential responsibility or liability for costs of enforcement, investigation, cleanup, governmental response, removal or remediation, for natural resources damages, property damage, personal injuries, or penalties or contribution, indemnification, cost recovery, compensation, or injunctive relief) arising out of, based on or related to (x) the presence of, release, spill, emission, leaking, dumping, pouring, deposit, disposal , discharge, leaching or migration into the environment (each a “Release”) or threatened Release of, or exposure to, any hazardous, toxic, explosive or radioactive substance, wastes or other substances or wastes of any nature regulated pursuant to any environmental law, at any location, whether or not owned, operated, leased or managed by the Company, or (y) circumstances forming the basis of any violation of any environmental law, environmental permit, license, registration or other authorization required under applicable environmental and/or public health law.
|
|
23.
|
Actions in connection with the Company’s development, use, sale, licensing, distribution, marketing or offer of products and/or services.
|
|
24.
|
Resolutions and/or actions relating to a merger of the Company, the issuance of shares or securities exercisable into shares of the Company, changing the share capital of the Company, formation of subsidiaries, reorganization, winding up or sale of all or part of the business, operations or shares the Company.
|
|
25.
|
Resolutions and/or actions relating to investments in the Company and/or the purchase or sale of assets, including the purchase or sale of companies and/or businesses, and/or investments in corporate or other entities and/or investments in traded securities and/or any other form of investment.
|
|
26.
|
Any administrative, regulatory or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance or violation by any governmental entity or other person alleging the failure of the Company, or any of the Company's business operations to comply with any statute, law, ordinance, rule, regulation, order or decree.
|
|
27.
|
Class actions or derivative actions regarding the Company.
|
|
28.
|
Any claim or demand, not covered by any of the categories of events described above, which, pursuant to any applicable law, a director or officer of the Company may be held liable to any government or agency thereof, or any person or entity, in connection with actions taken by such director or officer in such capacity.
|